{
  "schema_version": "0.1.0",
  "case_id": "HR-ML003",
  "record_classification": {
    "synthetic": true,
    "banner": "SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD",
    "real_historical_name": true,
    "public_release_status": "draft"
  },
  "identity": {
    "person_id": "ML003",
    "display_name": "Elvis Presley",
    "aliases": [
      "Elvis Aron Presley"
    ],
    "sex": "male",
    "era": "Mid-Late 20th Century",
    "nationality": "American",
    "historical_dates": {
      "birth": {
        "preferred": {
          "iso": "1935-01-08",
          "display": "January 8, 1935",
          "precision": "day",
          "calendar": "gregorian"
        },
        "alternatives": [
          {
            "date": {
              "iso": "1935",
              "display": "1935",
              "precision": "year",
              "calendar": "gregorian"
            },
            "source_ids": [
              "SRC-0009"
            ],
            "resolution_status": "preferred",
            "note": "Roster year agrees with the cited sources."
          }
        ]
      },
      "death": {
        "preferred": {
          "iso": "1977-08-16",
          "display": "August 16, 1977",
          "precision": "day",
          "calendar": "gregorian"
        },
        "alternatives": [
          {
            "date": {
              "iso": "1977",
              "display": "1977",
              "precision": "year",
              "calendar": "gregorian"
            },
            "source_ids": [
              "SRC-0009"
            ],
            "resolution_status": "preferred",
            "note": "Roster year agrees with the cited sources."
          }
        ]
      }
    },
    "synthetic_identity": {
      "mrn": "HR-ML003-SYN",
      "ssn": "000-03-4417",
      "date_of_birth": "1987-01-08",
      "name_policy": "real_historical_name",
      "fictional_facility": "St. Posthumous Health Center",
      "fictional_primary_clinician": "Coleman Ashby-Nakagawa, MD",
      "fictional_consultant": {
        "name": "Rosalind Eberhardt-Mensah, MD",
        "specialty": "Addiction Medicine"
      }
    }
  },
  "historical_timeline": [
    {
      "event_id": "EVT-0001",
      "date": {
        "iso": "1935-01-08",
        "display": "January 8, 1935",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "Born in Tupelo, Mississippi.",
      "claim_ids": [
        "CLM-0001"
      ]
    },
    {
      "event_id": "EVT-0002",
      "date": {
        "iso": "1953",
        "display": "1953",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "First recording; national fame from 1956; Army service from 1958 to 1960; Las Vegas engagements and tours in the 1970s. Believed never to have smoked or drunk alcohol.",
      "claim_ids": [
        "CLM-0002",
        "CLM-0011"
      ]
    },
    {
      "event_id": "EVT-0003",
      "date": {
        "iso": "1971",
        "display": "1971",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Acute angle-closure glaucoma; under an ophthalmologist's care from then on.",
      "claim_ids": [
        "CLM-0007"
      ]
    },
    {
      "event_id": "EVT-0004",
      "date": {
        "iso": "1973-10-15",
        "display": "October 15, 1973",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "Hospital stay in Memphis under an assumed name; later testimony says he was withdrawn from narcotic drugs.",
      "claim_ids": [
        "CLM-0003"
      ]
    },
    {
      "event_id": "EVT-0005",
      "date": {
        "iso": "1974-07",
        "display": "July 1974",
        "precision": "month",
        "calendar": "gregorian"
      },
      "summary": "A few weeks off at Graceland after a year of engagements and tours.",
      "claim_ids": [
        "CLM-0002"
      ]
    },
    {
      "event_id": "EVT-0006",
      "date": {
        "iso": "1974-08-19",
        "display": "August 19, 1974",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "Las Vegas engagement, then a tour from September 27 to October 14.",
      "claim_ids": [
        "CLM-0015"
      ]
    },
    {
      "event_id": "EVT-0007",
      "date": {
        "iso": "1975-01-28",
        "display": "January 28, 1975",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "Two hospital stays in 1975, for abdominal problems and swelling and then for breathlessness and swelling; reported treatment for hypertension and a blocked, enlarged colon.",
      "claim_ids": [
        "CLM-0004",
        "CLM-0005"
      ]
    },
    {
      "event_id": "EVT-0008",
      "date": {
        "iso": "1975",
        "display": "1975 to 1977",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "About 19,000 doses of stimulants, sedatives and painkillers prescribed by one physician in his last 30 months, with drugs also from other sources.",
      "claim_ids": [
        "CLM-0009"
      ]
    },
    {
      "event_id": "EVT-0009",
      "date": {
        "iso": "1977-08-16",
        "display": "August 16, 1977",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "Dies at Graceland at 42; the cause is disputed. Overweight in his last years; his glaucoma is later interpreted as steroid-induced.",
      "claim_ids": [
        "CLM-0012",
        "CLM-0013",
        "CLM-0014",
        "CLM-0006",
        "CLM-0008"
      ]
    },
    {
      "event_id": "EVT-0010",
      "date": {
        "iso": "1981-11-04",
        "display": "November 4, 1981",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "His physician is acquitted of overprescribing after testimony that he was addicted to prescribed drugs.",
      "claim_ids": [
        "CLM-0010"
      ]
    }
  ],
  "claims": [
    {
      "claim_id": "CLM-0001",
      "statement": "Elvis Aron Presley was born in a two-room house in Tupelo, Mississippi, on January 8, 1935; his family moved to Memphis when he was 13.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports",
          "locator": "born in a two-room house in Tupelo, Miss., on Jan. 8, 1935; moved to Memphis when he was 13"
        },
        {
          "source_id": "SRC-0009",
          "relationship": "context",
          "locator": "roster birth year 1935"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0002",
      "statement": "He made his first record in 1953, became a national star in 1956, served in the Army in West Germany from 1958 to 1960, and by the 1970s performed long engagements in Las Vegas and toured constantly. In 1974 he played Las Vegas from January 26 to February 9, toured through much of March, including four shows in Memphis on March 16 and 17 and a recorded show there on March 20, played Lake Tahoe from May 16 to 26, toured again in mid-June, and took a few weeks off at Graceland from early July.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "Anchors the performing and touring schedule in the modern social history and the timing of the index visit.",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports",
          "locator": "recorded his first song in 1953; Army 1958; Las Vegas in the 70's"
        },
        {
          "source_id": "SRC-0002",
          "relationship": "supports",
          "locator": "1974 engagements; takes a few weeks off, starting in early July"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0003",
      "statement": "From October 15 to November 1, 1973, he was treated at Baptist Memorial Hospital in Memphis under an assumed name; at the 1981 trial of his physician, an internal medicine specialist who reviewed the records testified that the consulting physicians were \"withdrawing him from narcotic drugs.\"",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "The anchor for the synthetic opioid use disorder; recorded as trial testimony reported by a wire service.",
      "source_links": [
        {
          "source_id": "SRC-0003",
          "relationship": "supports",
          "locator": "treated at Baptist Hospital from Oct. 15 until Nov. 1, 1973; withdrawing him from narcotic drugs; false name"
        }
      ],
      "release_status": "draft",
      "sensitive_content": true
    },
    {
      "claim_id": "CLM-0004",
      "statement": "He was treated at Baptist Hospital again from January 28 to February 13, 1975, when the admission note recorded abdominal problems and swelling of the face, hands and legs, and from August 21 to September 25, 1975, for shortness of breath and swelling. In 1977 the medical examiner said that the drugs he found were those prescribed for hypertension and a blockage of the colon, for which Presley had been hospitalized twice in 1975.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "History after the index visit; anchors the synthetic hypertension and constipation.",
      "source_links": [
        {
          "source_id": "SRC-0003",
          "relationship": "supports",
          "locator": "Jan. 28 to Feb. 13, 1975; Aug. 21 to Sept. 25, 1975; abdominal problems; swelling"
        },
        {
          "source_id": "SRC-0001",
          "relationship": "supports",
          "locator": "prescribed for hypertension and a blockage of the colon, for which he had been hospitalized twice in 1975"
        },
        {
          "source_id": "SRC-0009",
          "relationship": "context",
          "locator": "roster leads: hypertension, megacolon"
        }
      ],
      "release_status": "draft",
      "sensitive_content": true
    },
    {
      "claim_id": "CLM-0005",
      "statement": "In 1977 an unnamed Baptist Hospital employee told Rolling Stone that he had been treated there for \"hypertension, enlarged colon, gastroenteritis, stomach inflammation,\" had \"a severe liver condition,\" had received cortisone, and weighed at least 230 pounds; the hospital's doctors discounted a suggestion of lupus.",
      "evidence_grade": "D",
      "certainty": "probable",
      "clinical_interpretation": "An anonymous contemporary report; recorded as history only and not used for any modern diagnosis beyond the synthetic liver tests.",
      "source_links": [
        {
          "source_id": "SRC-0004",
          "relationship": "supports",
          "locator": "treating him for everything; a severe liver condition; at least 230 pounds"
        }
      ],
      "release_status": "draft",
      "sensitive_content": true
    },
    {
      "claim_id": "CLM-0006",
      "statement": "He was about six feet tall and had once weighed about 175 pounds; in his last years he was reported to be overweight and at times appeared bloated on stage.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "Anchors the synthetic weight gain and obesity, which the modern episode treats without stigma.",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports",
          "locator": "used to carry about 175 pounds on a 6-foot frame, had been plagued with overweight; sometimes appeared bloated"
        },
        {
          "source_id": "SRC-0009",
          "relationship": "context",
          "locator": "roster lead: obesity"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0007",
      "statement": "He had glaucoma, including an episode of acute angle-closure glaucoma in 1971, and was under the care of one ophthalmologist from 1971 on.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "Anchors the synthetic glaucoma and the ophthalmology follow-up.",
      "source_links": [
        {
          "source_id": "SRC-0005",
          "relationship": "supports",
          "locator": "an episode of acute angle closure glaucoma in 1971; main ophthalmologist from 1971"
        },
        {
          "source_id": "SRC-0009",
          "relationship": "context",
          "locator": "roster lead: glaucoma"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0008",
      "statement": "A 2025 ophthalmology review interprets his glaucoma as steroid-induced, from lifelong use of steroids both prescribed and self-administered, with secondary angle closure most likely due to anterior uveitis.",
      "evidence_grade": "R",
      "certainty": "probable",
      "clinical_interpretation": "Retrospective interpretation; the modern diagnosis of glaucoma secondary to drugs is synthetic.",
      "source_links": [
        {
          "source_id": "SRC-0005",
          "relationship": "supports",
          "locator": "steroid-induced glaucoma caused by a life-long use of steroids, both prescribed and self-administered"
        }
      ],
      "release_status": "draft",
      "sensitive_content": true
    },
    {
      "claim_id": "CLM-0009",
      "statement": "At the 1981 trial of his physician, George Nichopoulos, prosecutors showed that the physician had prescribed about 19,000 doses of stimulants, sedatives and painkillers for him in the last 30 months of his life, including 1,679 addictive pills in 205 days between the two 1975 hospital stays; the defense argued that he obtained drugs from many other sources, including amphetamines mailed from the West Coast, and a detective testified to collecting prescriptions from 140 Memphis pharmacies.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "Documented history of prescribed controlled drugs from several sources; anchors the synthetic multiple-prescriber history, the prescription drug monitoring program review and the single-prescriber agreement. No decision or statement in the modern episode is attributed to any real person.",
      "source_links": [
        {
          "source_id": "SRC-0006",
          "relationship": "supports",
          "locator": "19,000 addictive pills during the last 30 months"
        },
        {
          "source_id": "SRC-0003",
          "relationship": "supports",
          "locator": "1,679 addictive pills over a 205-day period; amphetamines mailed from the West Coast"
        },
        {
          "source_id": "SRC-0007",
          "relationship": "supports",
          "locator": "prescriptions collected from 140 pharmacies"
        },
        {
          "source_id": "SRC-0009",
          "relationship": "context",
          "locator": "roster lead: 10,000+ controlled substance doses in final year"
        }
      ],
      "release_status": "draft",
      "sensitive_content": true
    },
    {
      "claim_id": "CLM-0010",
      "statement": "Testimony at the trial described him as addicted to prescribed stimulants, sedatives and painkillers; the internal medicine specialist testified, \"Absolutely. He was addicted.\" On November 4, 1981, the jury acquitted the physician of overprescribing, citing his efforts to substitute placebos and intercept drugs sent from elsewhere; the physician then said that drugs \"may have played a part\" in the death.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "History after the modern episode; recorded without blame and without a modern statement attributed to any real person.",
      "source_links": [
        {
          "source_id": "SRC-0003",
          "relationship": "supports",
          "locator": "Absolutely. He was addicted"
        },
        {
          "source_id": "SRC-0006",
          "relationship": "supports",
          "locator": "found innocent; drugs may have played a part"
        },
        {
          "source_id": "SRC-0008",
          "relationship": "supports",
          "locator": "unanimous decision to acquit; the placebos, the intercepting of drugs"
        }
      ],
      "release_status": "draft",
      "sensitive_content": true
    },
    {
      "claim_id": "CLM-0011",
      "statement": "It was believed that he neither smoked nor drank alcohol.",
      "evidence_grade": "D",
      "certainty": "probable",
      "clinical_interpretation": "Anchors the synthetic alcohol and tobacco history.",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports",
          "locator": "It was believed that Mr. Presley neither smoked nor drank"
        }
      ],
      "release_status": "draft",
      "sensitive_content": true
    },
    {
      "claim_id": "CLM-0012",
      "statement": "On August 16, 1977, at 42, he was found unresponsive on the floor of his bathroom at Graceland, his home in Memphis, and was pronounced dead at Baptist Memorial Hospital.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "History only, recorded in one plain sentence.",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports",
          "locator": "pronounced dead an hour later at Baptist Memorial Hospital"
        },
        {
          "source_id": "SRC-0010",
          "relationship": "supports",
          "locator": "found unresponsive on the bathroom floor of his Graceland home"
        },
        {
          "source_id": "SRC-0002",
          "relationship": "supports",
          "locator": "August 16, 1977"
        },
        {
          "source_id": "SRC-0009",
          "relationship": "context",
          "locator": "roster death year 1977"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0013",
      "statement": "The cause of his death is disputed. The medical examiner gave cardiac arrhythmia, citing a history of mild hypertension and evidence of coronary artery disease, and later ruled it heart disease; the autopsy report was never released. Trial testimony said that 14 drugs, including codeine at ten times the maximum accepted level, were found in tissue samples, and later accounts attribute the death to multiple prescription drugs, to heart disease, or to straining with a severely enlarged colon.",
      "evidence_grade": "R",
      "certainty": "disputed",
      "clinical_interpretation": "History only; no cause of death is assumed in the modern episode.",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports",
          "locator": "cardiac arrhythmia; mild hypertension; coronary artery disease"
        },
        {
          "source_id": "SRC-0003",
          "relationship": "supports",
          "locator": "14 drugs, including 10 times the maximum accepted level of codeine"
        },
        {
          "source_id": "SRC-0006",
          "relationship": "supports",
          "locator": "officially ruled heart disease; autopsy report never released"
        },
        {
          "source_id": "SRC-0010",
          "relationship": "supports",
          "locator": "officially attributed to cardiac arrhythmia; long-term prescription drug use; megacolon"
        },
        {
          "source_id": "SRC-0009",
          "relationship": "context",
          "locator": "roster: polypharmacy"
        }
      ],
      "release_status": "draft",
      "sensitive_content": true
    },
    {
      "claim_id": "CLM-0014",
      "statement": "His physician later said that he had a severe form of megacolon, his colon about twice its normal diameter and impacted with stool at his death.",
      "evidence_grade": "R",
      "certainty": "possible",
      "clinical_interpretation": "Reported second-hand in a 2026 article quoting a biographer; recorded as a possibility only.",
      "source_links": [
        {
          "source_id": "SRC-0010",
          "relationship": "supports",
          "locator": "According to Nichopoulos, he suffered from a severe form of megacolon"
        },
        {
          "source_id": "SRC-0009",
          "relationship": "context",
          "locator": "roster lead: severe megacolon at autopsy"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0015",
      "statement": "After the weeks off in July 1974 he played the Las Vegas Hilton from August 19 to September 2, talking on stage about karate, and toured from September 27 to October 14, ending at Lake Tahoe on October 11 to 14.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "History after the index visit; the modern episode plans care around the same engagements.",
      "source_links": [
        {
          "source_id": "SRC-0002",
          "relationship": "supports",
          "locator": "August 19 - September 2, 1974; September 27 - October 14, 1974"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    }
  ],
  "sources": [
    {
      "source_id": "SRC-0001",
      "title": "Ivins M. Elvis Presley Dies; Rock Singer Was 42. The New York Times, August 17, 1977 (On This Day archive)",
      "publisher": "The New York Times",
      "url": "https://archive.nytimes.com/www.nytimes.com/learning/general/onthisday/big/0816.html",
      "source_type": "other",
      "published": "1977-08-17",
      "accessed": "2026-11-05",
      "rights_note": "Contemporary newspaper obituary; facts and short quotations used with citation."
    },
    {
      "source_id": "SRC-0002",
      "title": "Elvis History: 1974-1977",
      "publisher": "Elvis Presley's Graceland (Elvis Presley Enterprises)",
      "url": "https://www.graceland.com/1974---1977",
      "source_type": "other",
      "published": null,
      "accessed": "2026-11-05",
      "rights_note": "Official estate timeline; used for his 1974 engagements and the date of his death."
    },
    {
      "source_id": "SRC-0003",
      "title": "Elvis Presley was a drug addict and was hospitalized (UPI, October 23, 1981)",
      "publisher": "United Press International",
      "url": "https://www.upi.com/Archives/1981/10/23/Elvis-Presley-was-a-drug-addict-and-was-hospitalized/5661372657600/",
      "source_type": "other",
      "published": "1981-10-23",
      "accessed": "2026-11-05",
      "rights_note": "Contemporary wire report of trial testimony; facts and short quotations used with citation."
    },
    {
      "source_id": "SRC-0004",
      "title": "Flippo C. Elvis Presley: Funeral in Memphis. Rolling Stone, 1977",
      "publisher": "Rolling Stone",
      "url": "https://www.rollingstone.com/music/music-news/elvis-presley-funeral-in-memphis-61938/2/",
      "source_type": "other",
      "published": "1977-09-22",
      "accessed": "2026-11-05",
      "rights_note": "Contemporary magazine report quoting an unnamed hospital employee; used only for that report."
    },
    {
      "source_id": "SRC-0005",
      "title": "Zegers RH, Liu KC, Heutink J, Tennant F, Weinreb RN. Suspicious eyes - Elvis's glaucoma battle. J Med Biogr 2025;33(2):112-115 (PMID 39150457)",
      "publisher": "Journal of Medical Biography",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39150457/",
      "source_type": "scholarly",
      "published": "2025-05-01",
      "accessed": "2026-11-05",
      "rights_note": "Peer-reviewed historical article; only the PubMed abstract was read."
    },
    {
      "source_id": "SRC-0006",
      "title": "Murphy P. Details of Presley's death still unknown (UPI, November 7, 1981)",
      "publisher": "United Press International",
      "url": "https://www.upi.com/Archives/1981/11/07/Details-of-Presleys-death-still-unknown/2954373957200/",
      "source_type": "other",
      "published": "1981-11-07",
      "accessed": "2026-11-05",
      "rights_note": "Contemporary wire report on the trial verdict; facts and short quotations used with citation."
    },
    {
      "source_id": "SRC-0007",
      "title": "Elvis Presley was a drug addict and received 'staggering' amounts of drugs (UPI, October 13, 1981)",
      "publisher": "United Press International",
      "url": "https://www.upi.com/Archives/1981/10/13/Elvis-Presley-was-a-drug-addict-and-received-staggering/5295371793600/",
      "source_type": "other",
      "published": "1981-10-13",
      "accessed": "2026-11-05",
      "rights_note": "Contemporary wire report of the opening of the trial; used for the pharmacy prescriptions."
    },
    {
      "source_id": "SRC-0008",
      "title": "Thorsberg F. Jurors say Elvis doctor operated in good faith (UPI, November 5, 1981)",
      "publisher": "United Press International",
      "url": "https://www.upi.com/Archives/1981/11/05/Jurors-say-Elvis-doctor-operated-in-good-faith/6712373784400/",
      "source_type": "other",
      "published": "1981-11-05",
      "accessed": "2026-11-05",
      "rights_note": "Contemporary wire report on the jury's reasons; used for the acquittal."
    },
    {
      "source_id": "SRC-0009",
      "title": "HISTMED Master Roster v3",
      "publisher": "The Human Record project",
      "url": "https://humanrecord.example.org/internal/HISTMED_Master_Roster_v3.xlsx",
      "source_type": "other",
      "published": "2026-11-01",
      "accessed": "2026-11-05",
      "rights_note": "Internal source locator; inherited claims remain provisional until corroborated."
    },
    {
      "source_id": "SRC-0010",
      "title": "Wakeman G. How Did Elvis Presley Die?",
      "publisher": "HISTORY (A&E Television Networks)",
      "url": "https://www.history.com/articles/elvis-presley-death-cause",
      "source_type": "other",
      "published": "2026-02-19",
      "accessed": "2026-11-05",
      "rights_note": "Reference article quoting a biographer and The New York Times; used for the circumstances of death and the megacolon account."
    }
  ],
  "synthetic_episode": {
    "calendar_frame": "modern_shifted",
    "index_date": "2026-07-10",
    "index_age": 39,
    "date_shift_policy": "HR-DATE-SHIFT-1",
    "teaching_objective": "Polypharmacy and prescription opioid and sedative use disorders from several prescribers, in a 39-year-old touring singer who comes in for fatigue, weight gain, constipation, sleepiness and high blood pressure. The episode covers a brown-bag medication reconciliation and prescription drug monitoring program review that finds two opioids, two benzodiazepines and an appetite suppressant from five prescribers; a nonjudgmental DSM-5-TR assessment; naloxone at the first visit; a single-prescriber agreement; buprenorphine started in the office under the ASAM 2020 guideline, with the guideline's advice that taking a benzodiazepine is not a reason to withhold it; the benzodiazepines combined into diazepam and tapered slowly under the 2025 joint guideline; a structured safety assessment with means safety and the 988 Suicide & Crisis Lifeline; hypertension confirmed with home readings and treated under the 2025 AHA/ACC guideline; obesity treated without stigma with tirzepatide, which also treats obstructive sleep apnea; STOP-Bang and in-laboratory polysomnography because opioids make home testing unreliable; opioid-induced constipation; glaucoma that rules out phentermine and anticholinergic sleep aids; acute back pain managed on buprenorphine; and care planned around a performing and touring schedule.",
    "visit_schedule": [
      {
        "encounter_id": "ENC-001",
        "date": "2026-07-10",
        "purpose": "Establishing primary care for fatigue, weight gain, constipation, daytime sleepiness and high blood pressure, with many prescribed drugs from several prescribers: a full medication reconciliation and prescription drug monitoring program review, a nonjudgmental substance use assessment, safety, and an addiction medicine referral"
      },
      {
        "encounter_id": "ENC-002",
        "date": "2026-07-17",
        "purpose": "One-week review, seen the same day by addiction medicine: diagnoses, buprenorphine started in the office, the benzodiazepines combined into one, the sleep study and home blood pressure results"
      },
      {
        "encounter_id": "ENC-003",
        "date": "2026-08-07",
        "purpose": "Three-week review on buprenorphine: withdrawal and cravings, the first benzodiazepine taper step, blood pressure treatment, CPAP, constipation and weight, and planning for a Las Vegas engagement"
      },
      {
        "encounter_id": "ENC-006",
        "date": "2026-08-14",
        "purpose": "Periodic adult preventive visit"
      },
      {
        "encounter_id": "ENC-007",
        "date": "2026-09-09",
        "purpose": "Same-day sick visit for low back pain"
      },
      {
        "encounter_id": "ENC-004",
        "date": "2026-09-23",
        "purpose": "Ten-week review after the Las Vegas engagement and a back strain: buprenorphine, the taper, weight treatment, sleep apnea and planning for a three-week tour"
      },
      {
        "encounter_id": "ENC-005",
        "date": "2026-10-28",
        "purpose": "Four-month review after the tour: recovery, the taper, blood pressure, weight, liver tests, sleep and the plan ahead"
      }
    ]
  },
  "clinical": {
    "problems": [
      {
        "id": "PRB-001",
        "display": "Fatigue, weight gain of about 14 kg in two years, constipation with a bowel movement every five to seven days, loud snoring with daytime sleepiness, and high blood pressure readings, in a man taking two opioids, two benzodiazepines and an appetite suppressant from five prescribers; under evaluation with addiction medicine, a sleep study and home blood pressure readings",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "R53.83",
            "display": "Other fatigue",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0009",
            "CLM-0010",
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic presenting problem anchored to the documented prescribed drugs and weight gain; superseded when the consultation and tests made the diagnoses.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        },
        "clinical_status": "resolved",
        "verification_status": "confirmed",
        "problem_placement": "active",
        "abatement_date": "2026-07-17"
      },
      {
        "id": "PRB-002",
        "display": "Obesity, class 1 (BMI 32.5), with prediabetes (hemoglobin A1c 5.8%); recorded without stigma; weight gain began with long touring schedules, night eating after shows and an appetite suppressant that stopped working",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "E66.811",
            "display": "Obesity, class 1",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic modern diagnosis anchored to his documented weight gain.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "both_with_link"
      },
      {
        "id": "PRB-003",
        "display": "Glaucoma secondary to steroids, both eyes, mild stage, after an acute angle-closure episode treated years ago; intraocular pressure controlled on latanoprost under his ophthalmologist; anticholinergic and sympathomimetic drugs to be avoided",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "H40.63X1",
            "display": "Glaucoma secondary to drugs, bilateral, mild stage",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0008"
          ],
          "synthetic_reason": "Synthetic modern diagnosis anchored to his documented glaucoma and the retrospective interpretation of it as steroid-induced; not a claim about his real eyes.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "both_with_link"
      },
      {
        "id": "PRB-004",
        "display": "Opioid use disorder, severe, with prescription opioids from more than one prescriber (seven DSM-5-TR criteria, tolerance and withdrawal counted because the opioids were not taken as prescribed); on buprenorphine from the consultation; synthetic modern episode linked to his documented withdrawal from narcotic drugs and prescribed painkillers",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "F11.20",
            "display": "Opioid dependence, uncomplicated",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0009",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic modern diagnosis made at the addiction medicine consultation; person-first language; not a claim about his real diagnosis.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "both_with_link",
        "recorded_date": "2026-07-17"
      },
      {
        "id": "PRB-005",
        "display": "Sedative, hypnotic, or anxiolytic use disorder (benzodiazepines), moderate (five DSM-5-TR criteria), with two benzodiazepines from two prescribers; combined into diazepam and tapering slowly; synthetic modern episode linked to his documented prescribed sedatives",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "F13.20",
            "display": "Sedative, hypnotic or anxiolytic dependence, uncomplicated",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0009",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic modern diagnosis made at the consultation; not a claim about his real diagnosis.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "both_with_link",
        "recorded_date": "2026-07-17"
      },
      {
        "id": "PRB-006",
        "display": "Hypertension, stage 2, confirmed by a home average of 146/94 a week after stopping phentermine; ECG and urine albumin normal",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "I10",
            "display": "Essential (primary) hypertension",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0004"
          ],
          "synthetic_reason": "Synthetic modern diagnosis confirmed with home readings, anchored to his documented hypertension.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "both_with_link",
        "recorded_date": "2026-07-17"
      },
      {
        "id": "PRB-007",
        "display": "Obstructive sleep apnea, moderate (apnea-hypopnea index 26 an hour, central apnea index 4, oxygen nadir 80% on in-laboratory polysomnography), worsened by opioids and benzodiazepines; on CPAP",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "G47.33",
            "display": "Obstructive sleep apnea (adult) (pediatric)",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern diagnosis from a synthetic sleep study.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active",
        "recorded_date": "2026-07-17"
      },
      {
        "id": "PRB-008",
        "display": "Opioid-induced constipation (Rome IV), improving after the change to buprenorphine; no alarm features",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "K59.03",
            "display": "Drug induced constipation",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0004",
            "CLM-0014"
          ],
          "synthetic_reason": "Synthetic modern diagnosis anchored to his documented blockage of the colon; not a claim about megacolon.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "both_with_link",
        "recorded_date": "2026-07-17"
      },
      {
        "id": "PRB-009",
        "display": "Acute low back strain after karate practice, without radicular signs or red flags, in a man on buprenorphine; resolved",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "S39.012A",
            "display": "Strain of muscle, fascia and tendon of lower back, initial encounter",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic acute injury; not a historical claim.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        },
        "clinical_status": "resolved",
        "verification_status": "confirmed",
        "problem_placement": "active",
        "recorded_date": "2026-09-09",
        "abatement_date": "2026-09-23"
      }
    ],
    "medications": [
      {
        "id": "MED-001",
        "display": "Hydromorphone 4 mg oral tablet, prescribed elsewhere as one tablet every four to six hours as needed for back and neck pain; taking about five a day (20 mg, 100 MME); continued by this clinic only, at the verified dose and seven days at a time, until the addiction medicine consultation",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "897702",
            "display": "hydromorphone hydrochloride 4 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 4,
          "period_unit": "h",
          "text": "Up to five tablets a day; seven-day supply"
        },
        "start_date": "2026-07-10",
        "end_date": "2026-07-17",
        "indication_problem_ids": [
          "PRB-001"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0009",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic long-term opioid prescription anchored to the documented narcotic drugs; not stopped abruptly.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "MED-002",
        "display": "Oxycodone 10 mg and acetaminophen 325 mg oral tablet, prescribed by a second prescriber; taking about three a day (45 MME); continued by this clinic only, seven days at a time, until the consultation",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "1049214",
            "display": "acetaminophen 325 MG / oxycodone hydrochloride 10 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 8,
          "period_unit": "h",
          "text": "Up to three tablets a day; seven-day supply"
        },
        "start_date": "2026-07-10",
        "end_date": "2026-07-17",
        "indication_problem_ids": [
          "PRB-001"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0009",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic second opioid prescription from another prescriber.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "MED-003",
        "display": "Diazepam 10 mg oral tablet, one tablet three times daily, prescribed elsewhere for anxiety; continued by this clinic only, seven days at a time",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "197589",
            "display": "diazepam 10 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 8,
          "period_unit": "h",
          "text": "One tablet three times daily; seven-day supply"
        },
        "start_date": "2026-07-10",
        "end_date": "2026-07-17",
        "indication_problem_ids": [
          "PRB-001"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0009",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic long-term benzodiazepine prescription anchored to the documented sedatives; not stopped abruptly because of the risk of withdrawal seizures.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "MED-004",
        "display": "Alprazolam 1 mg oral tablet, up to three a day as needed, prescribed by a fourth prescriber while on tour; continued by this clinic only, at the verified dose, seven days at a time",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "197321",
            "display": "alprazolam 1 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 8,
          "period_unit": "h",
          "text": "Up to three tablets a day; seven-day supply"
        },
        "start_date": "2026-07-10",
        "end_date": "2026-07-17",
        "indication_problem_ids": [
          "PRB-001"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0009",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic second benzodiazepine from another prescriber.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "MED-005",
        "display": "Phentermine 37.5 mg oral tablet each morning, prescribed by a weight clinic; stopped today because of high blood pressure and his glaucoma",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "803353",
            "display": "phentermine hydrochloride 37.5 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "Stopped"
        },
        "start_date": "2026-07-10",
        "end_date": "2026-07-10",
        "indication_problem_ids": [
          "PRB-002"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic stimulant appetite suppressant found at medication reconciliation and stopped; the label lists glaucoma and uncontrolled hypertension as reasons not to use it.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "MED-006",
        "display": "Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologist",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "314072",
            "display": "latanoprost 0.05 MG/ML Ophthalmic Solution",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "[drp]"
        },
        "route": "ophthalmic",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "One drop in each eye at bedtime"
        },
        "start_date": "2026-07-10",
        "indication_problem_ids": [
          "PRB-003"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007"
          ],
          "synthetic_reason": "Synthetic glaucoma treatment from his ophthalmologist, continued.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "MED-007",
        "display": "Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bag",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "1725059",
            "display": "naloxone hydrochloride 40 MG/ML Nasal Spray",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "nasal",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "One spray for a suspected overdose; call 911"
        },
        "start_date": "2026-07-10",
        "indication_problem_ids": [
          "PRB-001"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic overdose-prevention prescription for a man taking opioids with benzodiazepines.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "MED-008",
        "display": "Polyethylene glycol 3350, 17 g powder in a glass of water once daily",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "876193",
            "display": "polyethylene glycol 3350 17000 MG Powder for Oral Solution",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 17,
          "unit": "g"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "17 g in water once daily"
        },
        "start_date": "2026-07-10",
        "indication_problem_ids": [
          "PRB-001"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic first-line osmotic laxative for constipation on opioids.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "MED-009",
        "display": "Senna 8.6 mg oral tablet, two tablets at bedtime",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "312935",
            "display": "sennosides, USP 8.6 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 2,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "Two tablets at bedtime"
        },
        "start_date": "2026-07-10",
        "end_date": "2026-08-07",
        "indication_problem_ids": [
          "PRB-001"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic stimulant laxative added to polyethylene glycol.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "MED-010",
        "display": "Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily, which may be split into one film twice daily; started in the office at the consultation; seven-day supplies at first, from this clinic only",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "1010604",
            "display": "buprenorphine 8 MG / naloxone 2 MG Sublingual Film",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 2,
          "unit": "1"
        },
        "route": "sublingual",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "Two films once daily, or one film twice daily"
        },
        "start_date": "2026-07-17",
        "indication_problem_ids": [
          "PRB-004"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0009",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic medication for opioid use disorder, started in the office with a COWS score of 12 about 18 hours after the last hydromorphone.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "MED-011",
        "display": "Diazepam 10 mg oral tablet, one tablet four times daily (40 mg a day), replacing both diazepam 10 mg three times daily and alprazolam; held steady until buprenorphine is stable",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "197589",
            "display": "diazepam 10 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 6,
          "period_unit": "h",
          "text": "One tablet four times daily; seven-day supply"
        },
        "start_date": "2026-07-17",
        "end_date": "2026-08-07",
        "indication_problem_ids": [
          "PRB-005"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0009",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic consolidation of two benzodiazepines into one long-acting drug before tapering.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "MED-012",
        "display": "Diazepam 10 mg oral tablet, one tablet three times daily, with diazepam 2 mg tablets for the taper steps; dispensed two weeks at a time",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "197589",
            "display": "diazepam 10 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 8,
          "period_unit": "h",
          "text": "One tablet three times daily with the 2 mg tablets as scheduled"
        },
        "start_date": "2026-08-07",
        "indication_problem_ids": [
          "PRB-005"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0009",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic taper base dose.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "MED-013",
        "display": "Diazepam 2 mg oral tablet on the written taper schedule: three a day (36 mg a day in all) from the three-week visit, one a day (32 mg) from the ten-week visit, stopped at four months (30 mg)",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "197590",
            "display": "diazepam 2 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 8,
          "period_unit": "h",
          "text": "Per the written taper schedule"
        },
        "start_date": "2026-08-07",
        "end_date": "2026-10-28",
        "indication_problem_ids": [
          "PRB-005"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0009",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic taper steps of about 10% every four to six weeks, held during the Las Vegas engagement.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "MED-014",
        "display": "Amlodipine 5 mg and valsartan 160 mg oral tablet, one tablet daily",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "722134",
            "display": "amlodipine 5 MG / valsartan 160 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "One tablet daily"
        },
        "start_date": "2026-07-17",
        "indication_problem_ids": [
          "PRB-006"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic single-pill combination of two first-line drugs for stage 2 hypertension.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "MED-015",
        "display": "Tirzepatide 2.5 mg/0.5 mL auto-injector, 2.5 mg under the skin once weekly",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "2601761",
            "display": "0.5 ML tirzepatide 5 MG/ML Auto-Injector",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 0.5,
          "unit": "mL"
        },
        "route": "subcutaneous",
        "frequency": {
          "period": 1,
          "period_unit": "wk",
          "text": "2.5 mg once weekly"
        },
        "start_date": "2026-08-07",
        "end_date": "2026-09-23",
        "indication_problem_ids": [
          "PRB-002",
          "PRB-007"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic starting dose for obesity with obstructive sleep apnea.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "MED-016",
        "display": "Tirzepatide 5 mg/0.5 mL auto-injector, 5 mg under the skin once weekly",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "2601743",
            "display": "0.5 ML tirzepatide 10 MG/ML Auto-Injector",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 0.5,
          "unit": "mL"
        },
        "route": "subcutaneous",
        "frequency": {
          "period": 1,
          "period_unit": "wk",
          "text": "5 mg once weekly"
        },
        "start_date": "2026-09-23",
        "indication_problem_ids": [
          "PRB-002",
          "PRB-007"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic dose increase after six weeks without troublesome side effects.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "MED-017",
        "display": "Naproxen 500 mg oral tablet, one tablet twice daily with food for five days",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "198014",
            "display": "naproxen 500 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 12,
          "period_unit": "h",
          "text": "One tablet twice daily with food for five days"
        },
        "start_date": "2026-09-09",
        "end_date": "2026-09-13",
        "indication_problem_ids": [
          "PRB-009"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic short NSAID course; kidney function normal; blood pressure to be checked at home.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      }
    ],
    "allergies": [
      {
        "id": "ALG-001",
        "display": "No known allergy",
        "status": "active",
        "assertion": "no_known_allergy",
        "substance": {
          "system": "http://snomed.info/sct",
          "code": "716186003",
          "display": "No known allergy"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic allergy assertion for EHR completeness; not a historical assertion.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      }
    ],
    "observations": [
      {
        "id": "OBS-HGB-V1",
        "display": "Hemoglobin [Mass/volume] in Blood",
        "label": "Hemoglobin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-10",
        "value": 15.1,
        "unit": "g/dL",
        "reference_range": {
          "low": 13.2,
          "high": 17.1
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "718-7",
            "display": "Hemoglobin [Mass/volume] in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic hemoglobin in the evaluation of fatigue; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-NA-V1",
        "display": "Sodium [Moles/volume] in Serum or Plasma",
        "label": "Sodium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-10",
        "value": 139,
        "unit": "mmol/L",
        "reference_range": {
          "low": 135,
          "high": 145
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2951-2",
            "display": "Sodium [Moles/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel at the hypertension and fatigue evaluation; fasting glucose mildly raised.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-K-V1",
        "display": "Potassium [Moles/volume] in Serum or Plasma",
        "label": "Potassium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-10",
        "value": 4.0,
        "unit": "mmol/L",
        "reference_range": {
          "low": 3.5,
          "high": 5.1
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2823-3",
            "display": "Potassium [Moles/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel at the hypertension and fatigue evaluation; fasting glucose mildly raised.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-CR-V1",
        "display": "Creatinine [Mass/volume] in Serum or Plasma",
        "label": "Creatinine",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-10",
        "value": 1.0,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.74,
          "high": 1.35
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2160-0",
            "display": "Creatinine [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel at the hypertension and fatigue evaluation; fasting glucose mildly raised.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-EGFR-V1",
        "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
        "label": "eGFR (CKD-EPI 2021)",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-10",
        "value": 98,
        "unit": "mL/min/{1.73_m2}",
        "reference_range": {
          "low": 60
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "98979-8",
            "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel at the hypertension and fatigue evaluation; fasting glucose mildly raised.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-GLU-V1",
        "display": "Glucose [Mass/volume] in Serum or Plasma",
        "label": "Glucose",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-10",
        "value": 104,
        "unit": "mg/dL",
        "reference_range": {
          "low": 70,
          "high": 99
        },
        "interpretation": "H",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2345-7",
            "display": "Glucose [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel at the hypertension and fatigue evaluation; fasting glucose mildly raised.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-A1C-V1",
        "display": "Hemoglobin A1c/Hemoglobin.total in Blood",
        "label": "Hemoglobin A1c",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-10",
        "value": 5.8,
        "unit": "%",
        "reference_range": {
          "high": 5.6
        },
        "interpretation": "H",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "4548-4",
            "display": "Hemoglobin A1c/Hemoglobin.total in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic hemoglobin A1c in the prediabetes range.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALT-V1",
        "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "ALT",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-10",
        "value": 72,
        "unit": "U/L",
        "reference_range": {
          "low": 7,
          "high": 55
        },
        "interpretation": "H",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1742-6",
            "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic liver tests: mildly raised, with obesity and a daily acetaminophen-containing opioid; not a claim about his real liver.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-AST-V1",
        "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "AST",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-10",
        "value": 52,
        "unit": "U/L",
        "reference_range": {
          "low": 8,
          "high": 48
        },
        "interpretation": "H",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1920-8",
            "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic liver tests: mildly raised, with obesity and a daily acetaminophen-containing opioid; not a claim about his real liver.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-GGT-V1",
        "display": "Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "GGT",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-10",
        "value": 78,
        "unit": "U/L",
        "reference_range": {
          "low": 8,
          "high": 61
        },
        "interpretation": "H",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2324-2",
            "display": "Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic liver tests: mildly raised, with obesity and a daily acetaminophen-containing opioid; not a claim about his real liver.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-TSH-V1",
        "display": "Thyrotropin [Units/volume] in Serum or Plasma",
        "label": "TSH",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-10",
        "value": 2.1,
        "unit": "m[IU]/L",
        "reference_range": {
          "low": 0.4,
          "high": 4.5
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "3016-3",
            "display": "Thyrotropin [Units/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic TSH in the evaluation of fatigue and weight gain; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-UACR-V1",
        "display": "Albumin/Creatinine [Mass Ratio] in Urine",
        "label": "Urine albumin-to-creatinine ratio",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-07-10",
        "value": 14,
        "unit": "mg/g{creat}",
        "reference_range": {
          "high": 29
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "9318-7",
            "display": "Albumin/Creatinine [Mass Ratio] in Urine",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic urine albumin-to-creatinine ratio at the hypertension evaluation; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ9-V1",
        "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
        "label": "PHQ-9",
        "status": "final",
        "effective_date": "2026-07-10",
        "value": 8,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "44261-6",
            "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic depression screen: mild symptoms; item 9 scored 0. Not a claim about his real mood.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-GAD7-V1",
        "display": "Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]",
        "label": "GAD-7",
        "status": "final",
        "effective_date": "2026-07-10",
        "value": 9,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "70274-6",
            "display": "Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic anxiety screen: mild symptoms.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-DAST10-V1",
        "display": "Total score [DAST-10]",
        "label": "DAST-10",
        "status": "final",
        "effective_date": "2026-07-10",
        "value": 7,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "82667-7",
            "display": "Total score [DAST-10]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0009",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic drug-use screen for the past 12 months: substantial problems with prescribed opioids and sedatives. Not a claim about his real use.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-AUDITC-V1",
        "display": "Total score [AUDIT-C]",
        "label": "AUDIT-C",
        "status": "final",
        "effective_date": "2026-07-10",
        "value": 0,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "75626-2",
            "display": "Total score [AUDIT-C]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic alcohol screen: no alcohol.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ9-V6",
        "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
        "label": "PHQ-9",
        "status": "final",
        "effective_date": "2026-08-14",
        "value": 5,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "44261-6",
            "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic PHQ-9 at the preventive visit; item 9 scored 0.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-CHOL-V6",
        "display": "Cholesterol [Mass/volume] in Serum or Plasma",
        "label": "Total cholesterol",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-14",
        "value": 214,
        "unit": "mg/dL",
        "reference_range": {
          "high": 199
        },
        "interpretation": "H",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2093-3",
            "display": "Cholesterol [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic lipid panel at the preventive visit, with obesity and prediabetes.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-HDL-V6",
        "display": "Cholesterol in HDL [Mass/volume] in Serum or Plasma",
        "label": "HDL cholesterol",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-14",
        "value": 38,
        "unit": "mg/dL",
        "reference_range": {
          "low": 40
        },
        "interpretation": "L",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2085-9",
            "display": "Cholesterol in HDL [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic lipid panel at the preventive visit, with obesity and prediabetes.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-LDL-V6",
        "display": "Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation",
        "label": "LDL cholesterol (calculated)",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-14",
        "value": 140,
        "unit": "mg/dL",
        "reference_range": {
          "high": 129
        },
        "interpretation": "H",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "13457-7",
            "display": "Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic lipid panel at the preventive visit, with obesity and prediabetes.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-TG-V6",
        "display": "Triglyceride [Mass/volume] in Serum or Plasma",
        "label": "Triglycerides",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-14",
        "value": 180,
        "unit": "mg/dL",
        "reference_range": {
          "high": 149
        },
        "interpretation": "H",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2571-8",
            "display": "Triglyceride [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic lipid panel at the preventive visit, with obesity and prediabetes.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-K-V3",
        "display": "Potassium [Moles/volume] in Serum or Plasma",
        "label": "Potassium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-07",
        "value": 4.4,
        "unit": "mmol/L",
        "reference_range": {
          "low": 3.5,
          "high": 5.1
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2823-3",
            "display": "Potassium [Moles/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic potassium and creatinine three weeks after starting valsartan; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-CR-V3",
        "display": "Creatinine [Mass/volume] in Serum or Plasma",
        "label": "Creatinine",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-07",
        "value": 1.04,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.74,
          "high": 1.35
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2160-0",
            "display": "Creatinine [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic potassium and creatinine three weeks after starting valsartan; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-EGFR-V3",
        "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
        "label": "eGFR (CKD-EPI 2021)",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-07",
        "value": 94,
        "unit": "mL/min/{1.73_m2}",
        "reference_range": {
          "low": 60
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "98979-8",
            "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic potassium and creatinine three weeks after starting valsartan; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ9-V3",
        "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
        "label": "PHQ-9",
        "status": "final",
        "effective_date": "2026-08-07",
        "value": 6,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "44261-6",
            "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic PHQ-9 three weeks after starting buprenorphine; item 9 scored 0.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-GAD7-V3",
        "display": "Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]",
        "label": "GAD-7",
        "status": "final",
        "effective_date": "2026-08-07",
        "value": 8,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "70274-6",
            "display": "Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic GAD-7; mild symptoms.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ9-V4",
        "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
        "label": "PHQ-9",
        "status": "final",
        "effective_date": "2026-09-23",
        "value": 5,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "44261-6",
            "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic PHQ-9 after the Las Vegas engagement; item 9 scored 0.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-GAD7-V4",
        "display": "Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]",
        "label": "GAD-7",
        "status": "final",
        "effective_date": "2026-09-23",
        "value": 7,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "70274-6",
            "display": "Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic GAD-7; mild symptoms.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-K-V5",
        "display": "Potassium [Moles/volume] in Serum or Plasma",
        "label": "Potassium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-28",
        "value": 4.3,
        "unit": "mmol/L",
        "reference_range": {
          "low": 3.5,
          "high": 5.1
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2823-3",
            "display": "Potassium [Moles/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel on valsartan; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-CR-V5",
        "display": "Creatinine [Mass/volume] in Serum or Plasma",
        "label": "Creatinine",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-28",
        "value": 1.02,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.74,
          "high": 1.35
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2160-0",
            "display": "Creatinine [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel on valsartan; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-EGFR-V5",
        "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
        "label": "eGFR (CKD-EPI 2021)",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-28",
        "value": 96,
        "unit": "mL/min/{1.73_m2}",
        "reference_range": {
          "low": 60
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "98979-8",
            "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel on valsartan; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-A1C-V5",
        "display": "Hemoglobin A1c/Hemoglobin.total in Blood",
        "label": "Hemoglobin A1c",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-28",
        "value": 5.5,
        "unit": "%",
        "reference_range": {
          "high": 5.6
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "4548-4",
            "display": "Hemoglobin A1c/Hemoglobin.total in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic hemoglobin A1c after weight loss on tirzepatide; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALT-V5",
        "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "ALT",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-28",
        "value": 44,
        "unit": "U/L",
        "reference_range": {
          "low": 7,
          "high": 55
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1742-6",
            "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic liver tests after stopping the acetaminophen-containing opioid and losing weight; now normal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-AST-V5",
        "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "AST",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-28",
        "value": 33,
        "unit": "U/L",
        "reference_range": {
          "low": 8,
          "high": 48
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1920-8",
            "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic liver tests after stopping the acetaminophen-containing opioid and losing weight; now normal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-GGT-V5",
        "display": "Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "GGT",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-28",
        "value": 55,
        "unit": "U/L",
        "reference_range": {
          "low": 8,
          "high": 61
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2324-2",
            "display": "Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic liver tests after stopping the acetaminophen-containing opioid and losing weight; now normal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ9-V5",
        "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
        "label": "PHQ-9",
        "status": "final",
        "effective_date": "2026-10-28",
        "value": 4,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "44261-6",
            "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic PHQ-9 at four months; item 9 scored 0.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "OBS-GAD7-V5",
        "display": "Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]",
        "label": "GAD-7",
        "status": "final",
        "effective_date": "2026-10-28",
        "value": 5,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "70274-6",
            "display": "Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic GAD-7; mild symptoms.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      }
    ],
    "procedures": [
      {
        "id": "PROC-001",
        "display": "Twelve-lead electrocardiogram at the evaluation of high blood pressure readings, before any change in his medicines: sinus rhythm at 92, normal axis, no left ventricular hypertrophy, QTc 436 ms",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "29303009",
            "display": "Electrocardiographic procedure",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "period": {
          "start": "2026-07-10",
          "end": "2026-07-10"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline ECG.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "PROC-002",
        "display": "Attended in-laboratory split-night polysomnography (chosen over home testing because he takes opioids and benzodiazepines): apnea-hypopnea index 26 an hour, central apnea index 4, oxygen nadir 80%; CPAP titrated to 11 cm H2O, which controlled events",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "60554003",
            "display": "Polysomnography",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "period": {
          "start": "2026-07-14",
          "end": "2026-07-14"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic sleep study between the intake and the consultation.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "PROC-003",
        "display": "Advance care planning conversation, about 20 minutes",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "713603004",
            "display": "Advance care planning",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "period": {
          "start": "2026-08-14",
          "end": "2026-08-14"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic voluntary advance care planning at the preventive visit.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      }
    ],
    "immunizations": [
      {
        "id": "IMM-001",
        "display": "Tdap vaccine; last tetanus booster more than ten years ago",
        "status": "completed",
        "date": "2026-08-14",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "115",
            "display": "Tdap",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic Tdap at the preventive visit.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "IMM-002",
        "display": "Hepatitis B vaccine (HepB-CpG), first of two doses, after serology showed no immunity",
        "status": "completed",
        "date": "2026-09-23",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "189",
            "display": "HepB-CpG",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic hepatitis B vaccination, recommended for adults aged 19 to 59.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "IMM-003",
        "display": "Hepatitis B vaccine (HepB-CpG), second of two doses",
        "status": "completed",
        "date": "2026-10-28",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "189",
            "display": "HepB-CpG",
            "validation_status": "validated",
            "validated_on": "2026-11-05"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic second hepatitis B dose, five weeks after the first.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      }
    ],
    "family_history": [],
    "past_medical_history": [
      {
        "id": "PMH-001",
        "display": "Glaucoma, with an acute angle-closure episode treated years earlier; under an ophthalmologist's care since",
        "historical_date": {
          "iso": "1971",
          "display": "1971",
          "precision": "year",
          "calendar": "gregorian"
        },
        "provenance": {
          "evidence_grade": "D",
          "claim_ids": [
            "CLM-0007"
          ],
          "synthetic_reason": null,
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "PMH-002",
        "display": "Hospital stay of about two weeks in which, by later testimony, he was withdrawn from narcotic drugs; recorded without detail",
        "historical_date": {
          "iso": "1973-10-15",
          "display": "October 15, 1973",
          "precision": "day",
          "calendar": "gregorian"
        },
        "provenance": {
          "evidence_grade": "D",
          "claim_ids": [
            "CLM-0003"
          ],
          "synthetic_reason": null,
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      }
    ],
    "encounters": [
      {
        "id": "ENC-001",
        "display": "Establishing primary care for fatigue, weight gain, constipation, daytime sleepiness and high blood pressure, with many prescribed drugs from several prescribers: a full medication reconciliation and prescription drug monitoring program review, a nonjudgmental substance use assessment, safety, and an addiction medicine referral",
        "status": "finished",
        "date": "2026-07-10",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "ENC-002",
        "display": "One-week review, seen the same day by addiction medicine: diagnoses, buprenorphine started in the office, the benzodiazepines combined into one, the sleep study and home blood pressure results",
        "status": "finished",
        "date": "2026-07-17",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-05"
        },
        "documentation": {
          "chief_complaint": "One-week review, seen the same day by addiction medicine",
          "hpi": {
            "narrative": "Mr. Presley returns one week after intake and is seen by Dr. Eberhardt-Mensah of addiction medicine on the same day. He has taken only the medicines this clinic prescribed, from one pharmacy, and brought the remaining tablets. As agreed, he took his last hydromorphone about 18 hours ago and his last oxycodone about 20 hours ago so that buprenorphine could be started today; he has yawning, a runny nose, aching legs, gooseflesh and loose stools. He took his usual diazepam and alprazolam last night. His in-laboratory sleep study three days ago showed moderate obstructive sleep apnea. His home blood pressure readings over six days, after stopping phentermine, averaged 146/94. His bowels opened twice this week on polyethylene glycol and senna. He has kept his firearms locked and the naloxone in the house. He says he is ready to start treatment before his engagement.",
            "elements": [
              {
                "label": "Last full-agonist opioid",
                "value": "Hydromorphone 18 hours ago; oxycodone 20 hours ago"
              },
              {
                "label": "Withdrawal",
                "value": "Yawning, rhinorrhea, aching, gooseflesh, loose stools; COWS 12 (moderate)"
              },
              {
                "label": "Sleep study",
                "value": "Apnea-hypopnea index 26; central apnea index 4; nadir 80%"
              },
              {
                "label": "Home blood pressure",
                "value": "Average 146/94 over six days"
              },
              {
                "label": "Bowels",
                "value": "Twice this week"
              }
            ]
          },
          "ros": [
            {
              "system": "Constitutional",
              "status": "positive",
              "finding": "Aching and chills from withdrawal"
            },
            {
              "system": "Gastrointestinal",
              "status": "positive",
              "finding": "Loose stools today; mild cramps"
            },
            {
              "system": "Eyes",
              "status": "positive",
              "finding": "Watery eyes; no pain or halos"
            },
            {
              "system": "Psychiatric",
              "status": "positive",
              "finding": "Anxious about withdrawal; no thoughts of suicide or self-harm"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Restless, yawning; blood pressure 146/94, pulse 102, temperature 37.0 °C"
            },
            {
              "system": "Eyes",
              "finding": "Pupils 5 mm and reactive; lacrimation"
            },
            {
              "system": "Skin",
              "finding": "Piloerection; sweating; no injection marks"
            },
            {
              "system": "Neurological",
              "finding": "Mild tremor of the outstretched hands; alert and oriented"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-004",
              "display": "Opioid use disorder, severe",
              "assessment": "Dr. Eberhardt-Mensah confirms opioid use disorder, severe, with seven DSM-5-TR criteria: more taken than intended, unsuccessful efforts to cut down, much time spent getting prescriptions from several prescribers, craving, continued use despite sleepiness and constipation, tolerance and withdrawal (counted because the opioids were not taken as prescribed). Buprenorphine is the treatment of choice; taking a benzodiazepine is not a reason to withhold it, but the combination calls for naloxone, a single prescriber and close follow-up. COWS 12 today, so buprenorphine was started in the office: 4 mg, then 4 mg after an hour, with withdrawal settling",
              "plan": [
                "Buprenorphine with naloxone 16 mg tomorrow and daily after that",
                "Full-agonist opioids stopped; remaining tablets taken back",
                "Weekly phone or video contact for the first month; counseling started",
                "Naloxone continued"
              ]
            },
            {
              "problem_id": "PRB-005",
              "display": "Benzodiazepine use disorder, moderate",
              "assessment": "Five criteria met; daily diazepam and alprazolam for years mean a risk of seizures if stopped quickly. The two benzodiazepines are combined into diazepam alone, a long-acting drug, at 40 mg a day, a cautious equivalent of his combined doses, and held there until buprenorphine is stable",
              "plan": [
                "Diazepam 10 mg four times daily; alprazolam stopped",
                "Taper by about 5 to 10% every two to four weeks once buprenorphine is stable, starting at the next visit if he is ready",
                "CBT for anxiety and insomnia"
              ]
            },
            {
              "problem_id": "PRB-007",
              "display": "Obstructive sleep apnea, moderate",
              "assessment": "Moderate obstructive sleep apnea, with a small central component that opioids and benzodiazepines can worsen; CPAP at 11 cm H2O controlled events in the titration",
              "plan": [
                "CPAP nightly, with a travel machine",
                "No sedative added for sleep"
              ]
            },
            {
              "problem_id": "PRB-006",
              "display": "Hypertension, stage 2",
              "assessment": "A home average of 146/94 a week after stopping phentermine confirms stage 2 hypertension, more than 10 mmHg above the diastolic target, so two first-line drugs are started together. Today's office reading is raised further by withdrawal",
              "plan": [
                "Amlodipine 5 mg with valsartan 160 mg once daily",
                "Potassium and creatinine in two to four weeks",
                "Home readings twice daily for a week before the next visit"
              ]
            },
            {
              "problem_id": "PRB-008",
              "display": "Opioid-induced constipation",
              "assessment": "Meets Rome IV criteria for opioid-induced constipation; buprenorphine usually constipates less than full agonists",
              "plan": [
                "Continue polyethylene glycol and senna"
              ]
            },
            {
              "problem_id": "PRB-001",
              "display": "Fatigue, weight gain, constipation, sleepiness and high blood pressure",
              "assessment": "Explained by the diagnoses made today; this presenting problem is closed",
              "plan": [
                "Followed under each diagnosis"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "medication_safety",
              "measure": "Buprenorphine dose, withdrawal symptoms, cravings and other opioid use",
              "cadence": "Every visit; weekly contact in the first month",
              "status": "completed_today",
              "detail": "COWS 12 before the first dose; 8 mg given in the office; 16 mg a day from tomorrow",
              "guideline_ids": [
                "GL-ASAM-OUD-2020"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Prescription drug monitoring program check",
              "cadence": "Before every controlled-substance prescription",
              "status": "completed_today",
              "detail": "Only this clinic's seven-day prescriptions since intake; the earlier prescribers notified that this clinic now prescribes",
              "guideline_ids": [
                "GL-CDC-PDMP",
                "GL-CDC-OPIOID-2022"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Urine drug test, including buprenorphine metabolite and fentanyl",
              "cadence": "At the start of treatment, then about monthly while doses are changing",
              "status": "completed_today",
              "detail": "Point-of-care test today: hydromorphone, oxycodone and benzodiazepines present; fentanyl and other drugs absent (narrative)",
              "guideline_ids": [
                "GL-ASAM-OUD-2020",
                "GL-CDC-OPIOID-2022"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Naloxone on hand and people taught to use it",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Two-pack at home and one in the tour bag; two friends trained",
              "guideline_ids": [
                "GL-CDC-OPIOID-2022",
                "GL-ASAM-OUD-2020"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Diazepam dose, withdrawal symptoms (anxiety, insomnia, tremor, sweats) and taper pace",
              "cadence": "Every two to four weeks during the taper",
              "status": "completed_today",
              "detail": "Diazepam 30 mg and alprazolam 3 mg a day combined into diazepam 40 mg a day; no taper step during the buprenorphine start",
              "guideline_ids": [
                "GL-BZD-TAPER-2025"
              ]
            },
            {
              "domain": "survey",
              "measure": "Suicide-risk review, safety plan, means safety (locked medicines and firearms) and the 988 Suicide & Crisis Lifeline",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "No thoughts of suicide or self-harm; firearms locked; medicines in a locked box; 988 in his phone",
              "guideline_ids": [
                "GL-SUICIDE-2024"
              ]
            },
            {
              "domain": "survey",
              "measure": "Mood (PHQ-9) and anxiety (GAD-7)",
              "cadence": "At baseline, four to six weeks after a change in treatment, then at each review",
              "status": "up_to_date",
              "detail": "PHQ-9 8 and GAD-7 9 at intake; repeat at the next visit",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-USPSTF-DEP-2023"
              ]
            },
            {
              "domain": "examination",
              "measure": "Office and home blood pressure (target below 130/80)",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Office 146/94 in withdrawal; home average 146/94; treatment started",
              "guideline_ids": [
                "GL-AHA-HTN-2025",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Electrocardiogram at diagnosis of hypertension",
              "cadence": "At diagnosis",
              "status": "up_to_date",
              "detail": "Normal at intake, QTc 436 ms",
              "guideline_ids": [
                "GL-AHA-HTN-2025",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Potassium and creatinine after starting an angiotensin receptor blocker",
              "cadence": "Two to four weeks after starting, then every six months",
              "status": "due",
              "detail": "Valsartan started today; check at the next visit",
              "guideline_ids": [
                "GL-AHA-HTN-2025",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Weight and BMI",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "108.6 kg, BMI 32.4",
              "guideline_ids": [
                "GL-AGA-OBESITY-2022",
                "GL-SURMOUNT-OSA-2024"
              ]
            },
            {
              "domain": "survey",
              "measure": "CPAP adherence (device data) and sleepiness (Epworth, recorded as narrative)",
              "cadence": "Within the first 30 to 90 days, then at each review",
              "status": "due",
              "detail": "Polysomnogram three days ago; CPAP starts this week",
              "guideline_ids": [
                "GL-AASM-PAP-2019",
                "GL-AASM-DX-2017"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Bowel frequency, straining and alarm features",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Twice this week; no blood, weight loss or vomiting",
              "guideline_ids": [
                "GL-AGA-OIC-2019",
                "GL-AGA-ACG-CIC-2023"
              ]
            },
            {
              "domain": "examination",
              "measure": "Glaucoma: drop adherence, eye symptoms, medicines that raise eye pressure or close the angle, and ophthalmology follow-up",
              "cadence": "Every visit; ophthalmology every three to six months while recently controlled",
              "status": "completed_today",
              "detail": "Latanoprost nightly; phentermine and the nonprescription diphenhydramine sleep aid stopped; no eye pain or halos; ophthalmology visit in September",
              "guideline_ids": [
                "GL-AAO-POAG-2020",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "referral",
              "measure": "Addiction medicine consultation",
              "cadence": "At diagnosis",
              "status": "completed_today",
              "detail": "Seen by Dr. Eberhardt-Mensah today",
              "guideline_ids": [
                "GL-ASAM-OUD-2020",
                "GL-BZD-TAPER-2025"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Touring plan: one named pharmacy, video visits while away, CPAP and naloxone in the tour bag, no dose change in the week before an engagement",
              "cadence": "Before each engagement or tour",
              "status": "up_to_date",
              "detail": "Las Vegas engagement in five weeks; plan to be written at the next visit",
              "guideline_ids": [
                "GL-ASAM-OUD-2020"
              ]
            }
          ],
          "follow_up": "Phone check tomorrow and weekly contact. Three-week review. Call or use naloxone and 911 for heavy sedation or slow breathing",
          "guideline_ids": [
            "GL-ASAM-OUD-2020",
            "GL-CDC-OPIOID-2022",
            "GL-CDC-PDMP",
            "GL-BZD-TAPER-2025",
            "GL-AHA-HTN-2025",
            "GL-AASM-PAP-2019",
            "GL-AGA-OIC-2019",
            "GL-SUICIDE-2024"
          ]
        }
      },
      {
        "id": "ENC-003",
        "display": "Three-week review on buprenorphine: withdrawal and cravings, the first benzodiazepine taper step, blood pressure treatment, CPAP, constipation and weight, and planning for a Las Vegas engagement",
        "status": "finished",
        "date": "2026-08-07",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-05"
        },
        "documentation": {
          "chief_complaint": "Three-week review on buprenorphine, before a Las Vegas engagement",
          "hpi": {
            "narrative": "Mr. Presley returns three weeks after starting buprenorphine. Withdrawal settled on the first day, and he has taken 16 mg every morning since, with mild cravings in the evenings after rehearsals and no other opioid. He had weekly phone contact and two counseling sessions. He has taken diazepam 10 mg four times daily and no alprazolam. He used CPAP on 82% of nights, for an average of 6.1 hours, and is less sleepy in the afternoons (Epworth 9). His home blood pressure has averaged 128/82 on amlodipine with valsartan, without ankle swelling or dizziness. His bowels open every one to two days, so he has stopped the senna. He is anxious about the three-week Las Vegas engagement starting in twelve days. He had to leave for a rehearsal before giving a urine sample.",
            "elements": [
              {
                "label": "Buprenorphine",
                "value": "16 mg daily for three weeks; mild evening cravings; no other opioid"
              },
              {
                "label": "Diazepam",
                "value": "40 mg a day; no alprazolam"
              },
              {
                "label": "CPAP",
                "value": "82% of nights, 6.1 hours average; Epworth 9"
              },
              {
                "label": "Home blood pressure",
                "value": "Average 128/82"
              },
              {
                "label": "Bowels",
                "value": "Every one to two days; senna stopped"
              },
              {
                "label": "Mood",
                "value": "PHQ-9 6; GAD-7 8"
              }
            ]
          },
          "ros": [
            {
              "system": "Constitutional",
              "status": "negative",
              "finding": "Energy better"
            },
            {
              "system": "Cardiovascular",
              "status": "negative",
              "finding": "No ankle swelling, dizziness or palpitations"
            },
            {
              "system": "Gastrointestinal",
              "status": "negative",
              "finding": "Bowels regular; no nausea"
            },
            {
              "system": "Psychiatric",
              "status": "positive",
              "finding": "Anxious about the engagement; no thoughts of suicide or self-harm"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Calm and alert; blood pressure 128/82, pulse 76; weight 108.2 kg"
            },
            {
              "system": "Eyes",
              "finding": "Pupils 3 mm, equal and reactive"
            },
            {
              "system": "Neurological",
              "finding": "No tremor or sedation"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-004",
              "display": "Opioid use disorder on buprenorphine",
              "assessment": "Stable on 16 mg with mild cravings and no other opioid use. Safety reviewed: no thoughts of suicide or self-harm; naloxone in the house and the tour bag",
              "plan": [
                "Continue 16 mg daily; prescriptions for the engagement sent to one named pharmacy in Las Vegas",
                "Weekly video visits while away",
                "Urine drug test at the next visit"
              ]
            },
            {
              "problem_id": "PRB-005",
              "display": "Benzodiazepine use disorder on diazepam",
              "assessment": "Stable on 40 mg a day with buprenorphine settled, so the taper begins, at about 10%",
              "plan": [
                "Diazepam 36 mg a day (10 mg three times daily with 2 mg three times daily)",
                "No further step during the engagement"
              ]
            },
            {
              "problem_id": "PRB-006",
              "display": "Hypertension, stage 2",
              "assessment": "Home average 128/82; potassium 4.4 and creatinine 1.04 three weeks after starting valsartan",
              "plan": [
                "Continue amlodipine with valsartan"
              ]
            },
            {
              "problem_id": "PRB-002",
              "display": "Obesity, class 1, with prediabetes",
              "assessment": "Weight 108.2 kg. With buprenorphine stable and his bowels regular, tirzepatide can be started; it treats both obesity and obstructive sleep apnea, and its gastrointestinal effects will be watched with his history of constipation",
              "plan": [
                "Tirzepatide 2.5 mg weekly, the first dose today",
                "Earlier main meal and more walking"
              ]
            },
            {
              "problem_id": "PRB-007",
              "display": "Obstructive sleep apnea on CPAP",
              "assessment": "Good early adherence and less sleepiness",
              "plan": [
                "Travel CPAP for the engagement"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "medication_safety",
              "measure": "Buprenorphine dose, withdrawal symptoms, cravings and other opioid use",
              "cadence": "Every visit; weekly contact in the first month",
              "status": "completed_today",
              "detail": "16 mg daily; no withdrawal after the first day; mild evening cravings; weekly calls done",
              "guideline_ids": [
                "GL-ASAM-OUD-2020"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Prescription drug monitoring program check",
              "cadence": "Before every controlled-substance prescription",
              "status": "completed_today",
              "detail": "Only this clinic's prescriptions",
              "guideline_ids": [
                "GL-CDC-PDMP",
                "GL-CDC-OPIOID-2022"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Urine drug test, including buprenorphine metabolite and fentanyl",
              "cadence": "At the start of treatment, then about monthly while doses are changing",
              "status": "deferred",
              "detail": "Not collected: he left for a rehearsal before giving a sample. No harm is evident: the monitoring program shows only this clinic's prescriptions and he reports no other use. Corrective action: sample to be collected at the start of the next visit",
              "guideline_ids": [
                "GL-ASAM-OUD-2020",
                "GL-CDC-OPIOID-2022"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Naloxone on hand and people taught to use it",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "At home and in the tour bag",
              "guideline_ids": [
                "GL-CDC-OPIOID-2022"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Diazepam dose, withdrawal symptoms (anxiety, insomnia, tremor, sweats) and taper pace",
              "cadence": "Every two to four weeks during the taper",
              "status": "completed_today",
              "detail": "First step today, 40 to 36 mg a day (10%); no withdrawal symptoms",
              "guideline_ids": [
                "GL-BZD-TAPER-2025"
              ]
            },
            {
              "domain": "survey",
              "measure": "Suicide-risk review, safety plan, means safety (locked medicines and firearms) and the 988 Suicide & Crisis Lifeline",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "No thoughts of suicide or self-harm; safety plan reviewed; firearms and medicines locked",
              "guideline_ids": [
                "GL-SUICIDE-2024"
              ]
            },
            {
              "domain": "survey",
              "measure": "Mood (PHQ-9) and anxiety (GAD-7)",
              "cadence": "At baseline, four to six weeks after a change in treatment, then at each review",
              "status": "completed_today",
              "detail": "PHQ-9 6 (item 9 scored 0); GAD-7 8",
              "observation_ids": [
                "OBS-PHQ9-V3",
                "OBS-GAD7-V3"
              ],
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-USPSTF-DEP-2023"
              ]
            },
            {
              "domain": "examination",
              "measure": "Office and home blood pressure (target below 130/80)",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Office 128/82; home average 128/82",
              "guideline_ids": [
                "GL-AHA-HTN-2025",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Potassium and creatinine after starting an angiotensin receptor blocker",
              "cadence": "Two to four weeks after starting, then every six months",
              "status": "completed_today",
              "detail": "Potassium 4.4, creatinine 1.04 three weeks after starting valsartan",
              "observation_ids": [
                "OBS-K-V3",
                "OBS-CR-V3",
                "OBS-EGFR-V3"
              ],
              "guideline_ids": [
                "GL-AHA-HTN-2025",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Weight and BMI",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "108.2 kg, BMI 32.3",
              "guideline_ids": [
                "GL-AGA-OBESITY-2022",
                "GL-SURMOUNT-OSA-2024"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Tirzepatide tolerance: nausea, vomiting, constipation, abdominal pain",
              "cadence": "At each dose step",
              "status": "completed_today",
              "detail": "Baseline before the first dose: no nausea; bowels every one to two days",
              "guideline_ids": [
                "GL-AGA-OBESITY-2022",
                "GL-SURMOUNT-OSA-2024"
              ]
            },
            {
              "domain": "survey",
              "measure": "CPAP adherence (device data) and sleepiness (Epworth, recorded as narrative)",
              "cadence": "Within the first 30 to 90 days, then at each review",
              "status": "completed_today",
              "detail": "82% of nights, 6.1 hours; Epworth 9",
              "guideline_ids": [
                "GL-AASM-PAP-2019",
                "GL-AASM-DX-2017"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Bowel frequency, straining and alarm features",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Every one to two days; senna stopped",
              "guideline_ids": [
                "GL-AGA-OIC-2019",
                "GL-AGA-ACG-CIC-2023"
              ]
            },
            {
              "domain": "examination",
              "measure": "Glaucoma: drop adherence, eye symptoms, medicines that raise eye pressure or close the angle, and ophthalmology follow-up",
              "cadence": "Every visit; ophthalmology every three to six months while recently controlled",
              "status": "completed_today",
              "detail": "Drops nightly; no eye symptoms; no new drug that affects eye pressure",
              "guideline_ids": [
                "GL-AAO-POAG-2020",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Touring plan: one named pharmacy, video visits while away, CPAP and naloxone in the tour bag, no dose change in the week before an engagement",
              "cadence": "Before each engagement or tour",
              "status": "completed_today",
              "detail": "Written plan for the Las Vegas engagement: one pharmacy, weekly video visits, travel CPAP, naloxone, no taper step while away",
              "guideline_ids": [
                "GL-ASAM-OUD-2020",
                "GL-BZD-TAPER-2025"
              ]
            }
          ],
          "follow_up": "Preventive visit next week. Weekly video visits during the engagement. Ten-week review after he returns",
          "guideline_ids": [
            "GL-ASAM-OUD-2020",
            "GL-CDC-OPIOID-2022",
            "GL-BZD-TAPER-2025",
            "GL-AHA-HTN-2025",
            "GL-AGA-OBESITY-2022",
            "GL-SURMOUNT-OSA-2024",
            "GL-AASM-PAP-2019",
            "GL-CMID-2026"
          ]
        }
      },
      {
        "id": "ENC-004",
        "display": "Ten-week review after the Las Vegas engagement and a back strain: buprenorphine, the taper, weight treatment, sleep apnea and planning for a three-week tour",
        "status": "finished",
        "date": "2026-09-23",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-05"
        },
        "documentation": {
          "chief_complaint": "Ten-week review after the Las Vegas engagement and a back strain, before a three-week tour",
          "hpi": {
            "narrative": "Mr. Presley returns after a three-week engagement in Las Vegas and two weeks after the sick visit for a back strain. The back pain settled within a week on split buprenorphine doses and naproxen, and he has gone back to 16 mg once each morning. He took no other opioid and no extra diazepam. He had video visits in the first and third weeks of the engagement; the second was missed when a rehearsal ran late, and a nurse called him the next day. He used the travel CPAP on most nights. He has had mild nausea for a day after each tirzepatide dose and no constipation. His weight is 105.1 kg. His ophthalmologist saw him last week, found his eye pressures controlled on latanoprost and made no change. His HIV and hepatitis C tests were nonreactive and his hepatitis B tests showed no immunity. The tour begins in four days.",
            "elements": [
              {
                "label": "Buprenorphine",
                "value": "16 mg daily; no other opioid; cravings rare"
              },
              {
                "label": "Diazepam",
                "value": "36 mg a day since the three-week visit; no withdrawal symptoms"
              },
              {
                "label": "Back strain",
                "value": "Resolved"
              },
              {
                "label": "Tirzepatide",
                "value": "2.5 mg weekly for six weeks; mild nausea for a day after each dose"
              },
              {
                "label": "Weight",
                "value": "105.1 kg, down 3.9 kg from intake"
              },
              {
                "label": "Ophthalmology",
                "value": "Pressures controlled; no change"
              },
              {
                "label": "Screening results",
                "value": "HIV and hepatitis C nonreactive; hepatitis B not immune"
              }
            ]
          },
          "ros": [
            {
              "system": "Constitutional",
              "status": "negative",
              "finding": "Energy good"
            },
            {
              "system": "Musculoskeletal",
              "status": "negative",
              "finding": "Back pain resolved"
            },
            {
              "system": "Gastrointestinal",
              "status": "positive",
              "finding": "Mild nausea for a day after each injection; bowels regular"
            },
            {
              "system": "Eyes",
              "status": "negative",
              "finding": "No pain or halos"
            },
            {
              "system": "Psychiatric",
              "status": "negative",
              "finding": "PHQ-9 5; no thoughts of suicide or self-harm"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Well; blood pressure 126/80, pulse 74; weight 105.1 kg, BMI 31.4"
            },
            {
              "system": "Back",
              "finding": "Full, painless range of motion"
            },
            {
              "system": "Neurological",
              "finding": "No tremor or sedation"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-004",
              "display": "Opioid use disorder on buprenorphine",
              "assessment": "Stable through an engagement and an acute pain episode without other opioid use. Urine drug test today: buprenorphine and norbuprenorphine and benzodiazepines present, no other opioid and no fentanyl. Safety reviewed: no thoughts of suicide or self-harm; naloxone in the tour bag",
              "plan": [
                "Continue 16 mg daily; tour prescriptions to the same named pharmacy chain",
                "Video visits weekly on tour at a fixed time with a backup slot"
              ]
            },
            {
              "problem_id": "PRB-005",
              "display": "Benzodiazepine use disorder on a diazepam taper",
              "assessment": "Six weeks at 36 mg without withdrawal; a step now, four days before the tour, was discussed; he preferred to take it today and agreed to hold if he has symptoms",
              "plan": [
                "Diazepam 32 mg a day (10 mg three times daily with 2 mg once daily)"
              ]
            },
            {
              "problem_id": "PRB-002",
              "display": "Obesity, class 1, with prediabetes",
              "assessment": "Down 3.9 kg (3.6%) with mild nausea only",
              "plan": [
                "Tirzepatide increased to 5 mg weekly"
              ]
            },
            {
              "problem_id": "PRB-009",
              "display": "Acute low back strain",
              "assessment": "Resolved without imaging; naproxen finished",
              "plan": [
                "Warm up before karate"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "medication_safety",
              "measure": "Buprenorphine dose, withdrawal symptoms, cravings and other opioid use",
              "cadence": "Every visit; weekly contact in the first month",
              "status": "completed_today",
              "detail": "16 mg daily; split dosing for one week during the back strain; no other opioid",
              "guideline_ids": [
                "GL-ASAM-OUD-2020"
              ]
            },
            {
              "domain": "survey",
              "measure": "Weekly video visits while away",
              "cadence": "Weekly during engagements and tours",
              "status": "deferred",
              "detail": "The second weekly video visit in Las Vegas was missed when a rehearsal ran late; a nurse reached him by phone the next day and found him well. No harm resulted. Corrective action: a fixed weekly time on tour with a backup slot the same day",
              "guideline_ids": [
                "GL-ASAM-OUD-2020"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Prescription drug monitoring program check",
              "cadence": "Before every controlled-substance prescription",
              "status": "completed_today",
              "detail": "Only this clinic's prescriptions, filled at the named pharmacies",
              "guideline_ids": [
                "GL-CDC-PDMP",
                "GL-CDC-OPIOID-2022"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Urine drug test, including buprenorphine metabolite and fentanyl",
              "cadence": "At the start of treatment, then about monthly while doses are changing",
              "status": "completed_today",
              "detail": "Collected at the start of the visit: buprenorphine, norbuprenorphine and benzodiazepines present; no other opioid; fentanyl absent (narrative)",
              "guideline_ids": [
                "GL-ASAM-OUD-2020",
                "GL-CDC-OPIOID-2022"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Naloxone on hand and people taught to use it",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "In the tour bag; two people trained",
              "guideline_ids": [
                "GL-CDC-OPIOID-2022"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Diazepam dose, withdrawal symptoms (anxiety, insomnia, tremor, sweats) and taper pace",
              "cadence": "Every two to four weeks during the taper",
              "status": "completed_today",
              "detail": "36 to 32 mg a day (11%) after six weeks at 36 mg; no withdrawal symptoms",
              "guideline_ids": [
                "GL-BZD-TAPER-2025"
              ]
            },
            {
              "domain": "survey",
              "measure": "Suicide-risk review, safety plan, means safety (locked medicines and firearms) and the 988 Suicide & Crisis Lifeline",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "No thoughts of suicide or self-harm; firearms and medicines locked",
              "guideline_ids": [
                "GL-SUICIDE-2024"
              ]
            },
            {
              "domain": "survey",
              "measure": "Mood (PHQ-9) and anxiety (GAD-7)",
              "cadence": "At each review",
              "status": "completed_today",
              "detail": "PHQ-9 5 (item 9 scored 0); GAD-7 7",
              "observation_ids": [
                "OBS-PHQ9-V4",
                "OBS-GAD7-V4"
              ],
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-USPSTF-DEP-2023"
              ]
            },
            {
              "domain": "examination",
              "measure": "Office and home blood pressure (target below 130/80)",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Office 126/80; home average 124/80",
              "guideline_ids": [
                "GL-AHA-HTN-2025",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Potassium and creatinine after starting an angiotensin receptor blocker",
              "cadence": "Two to four weeks after starting, then every six months",
              "status": "up_to_date",
              "detail": "Normal three weeks after starting; next at six months",
              "guideline_ids": [
                "GL-AHA-HTN-2025",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Weight and BMI",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "105.1 kg, BMI 31.4; down 3.9 kg",
              "guideline_ids": [
                "GL-AGA-OBESITY-2022",
                "GL-SURMOUNT-OSA-2024"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Tirzepatide tolerance: nausea, vomiting, constipation, abdominal pain",
              "cadence": "At each dose step",
              "status": "completed_today",
              "detail": "Mild nausea for a day after each dose; no vomiting or constipation; increased to 5 mg",
              "guideline_ids": [
                "GL-AGA-OBESITY-2022",
                "GL-SURMOUNT-OSA-2024"
              ]
            },
            {
              "domain": "survey",
              "measure": "CPAP adherence (device data) and sleepiness (Epworth, recorded as narrative)",
              "cadence": "Within the first 30 to 90 days, then at each review",
              "status": "completed_today",
              "detail": "86% of nights over the engagement; Epworth 7",
              "guideline_ids": [
                "GL-AASM-PAP-2019",
                "GL-AASM-DX-2017"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Bowel frequency, straining and alarm features",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Daily or every other day on polyethylene glycol",
              "guideline_ids": [
                "GL-AGA-OIC-2019",
                "GL-AGA-ACG-CIC-2023"
              ]
            },
            {
              "domain": "examination",
              "measure": "Glaucoma: drop adherence, eye symptoms, medicines that raise eye pressure or close the angle, and ophthalmology follow-up",
              "cadence": "Every visit; ophthalmology every three to six months while recently controlled",
              "status": "completed_today",
              "detail": "Ophthalmology last week: pressures controlled, no change; no new drug that affects eye pressure",
              "guideline_ids": [
                "GL-AAO-POAG-2020",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Touring plan: one named pharmacy, video visits while away, CPAP and naloxone in the tour bag, no dose change in the week before an engagement",
              "cadence": "Before each engagement or tour",
              "status": "completed_today",
              "detail": "Tour plan written: named pharmacy chain, fixed video visit time with backup, travel CPAP, naloxone",
              "guideline_ids": [
                "GL-ASAM-OUD-2020",
                "GL-BZD-TAPER-2025"
              ]
            }
          ],
          "follow_up": "First hepatitis B vaccine dose given today. Weekly video visits on tour. Four-month review after the tour",
          "guideline_ids": [
            "GL-ASAM-OUD-2020",
            "GL-CDC-OPIOID-2022",
            "GL-BZD-TAPER-2025",
            "GL-AHA-HTN-2025",
            "GL-AGA-OBESITY-2022",
            "GL-AASM-PAP-2019",
            "GL-AAO-POAG-2020",
            "GL-CDC-IMZ-2026"
          ]
        }
      },
      {
        "id": "ENC-005",
        "display": "Four-month review after the tour: recovery, the taper, blood pressure, weight, liver tests, sleep and the plan ahead",
        "status": "finished",
        "date": "2026-10-28",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-05"
        },
        "documentation": {
          "chief_complaint": "Four-month review after the tour",
          "hpi": {
            "narrative": "Mr. Presley returns two weeks after finishing a three-week tour. He kept every weekly video visit on tour. He has taken buprenorphine 16 mg every morning with rare cravings and no other opioid, and diazepam 32 mg a day without withdrawal symptoms; he sleeps about seven hours with CPAP, on 88% of nights, and his Epworth score is 6. His home blood pressure averages 122/78. On tirzepatide 5 mg weekly for five weeks he has had mild nausea once and no constipation, and his weight is 102.6 kg. His bowels open daily or every other day on polyethylene glycol. He has no eye symptoms. He has started walking each morning and eating his main meal before the show.",
            "elements": [
              {
                "label": "Buprenorphine",
                "value": "16 mg daily; rare cravings; no other opioid"
              },
              {
                "label": "Diazepam",
                "value": "32 mg a day for five weeks; no withdrawal symptoms"
              },
              {
                "label": "Weight",
                "value": "102.6 kg, down 6.4 kg (5.9%) from intake"
              },
              {
                "label": "Blood pressure",
                "value": "Home average 122/78"
              },
              {
                "label": "CPAP",
                "value": "88% of nights; Epworth 6"
              },
              {
                "label": "Liver tests",
                "value": "ALT 44, AST 33, GGT 55 U/L, now normal"
              }
            ]
          },
          "ros": [
            {
              "system": "Constitutional",
              "status": "negative",
              "finding": "Energy good; weight down"
            },
            {
              "system": "Gastrointestinal",
              "status": "negative",
              "finding": "Nausea once; bowels regular"
            },
            {
              "system": "Eyes",
              "status": "negative",
              "finding": "No pain, halos or vision change"
            },
            {
              "system": "Psychiatric",
              "status": "negative",
              "finding": "PHQ-9 4; no thoughts of suicide or self-harm"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Well; blood pressure 122/78, pulse 70; weight 102.6 kg, BMI 30.6"
            },
            {
              "system": "Neck",
              "finding": "Circumference 42 cm"
            },
            {
              "system": "Neurological",
              "finding": "No tremor or sedation"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-004",
              "display": "Opioid use disorder on buprenorphine",
              "assessment": "In early remission on buprenorphine: no use of other opioids and rare cravings for more than three months. Safety reviewed: no thoughts of suicide or self-harm; naloxone on hand",
              "plan": [
                "Continue 16 mg daily without a planned end; visits every four weeks",
                "Counseling continues"
              ]
            },
            {
              "problem_id": "PRB-005",
              "display": "Benzodiazepine use disorder on a diazepam taper",
              "assessment": "Five weeks at 32 mg without symptoms; the next step is due",
              "plan": [
                "Diazepam 30 mg a day (10 mg three times daily); the 2 mg tablets stopped",
                "Further steps of about 10% every four weeks, with CBT"
              ]
            },
            {
              "problem_id": "PRB-006",
              "display": "Hypertension, stage 2",
              "assessment": "At target on amlodipine with valsartan, helped by weight loss; potassium and creatinine normal",
              "plan": [
                "Continue; consider lowering the dose if weight loss continues and readings fall below 115/75"
              ]
            },
            {
              "problem_id": "PRB-002",
              "display": "Obesity, class 1, with prediabetes",
              "assessment": "Down 5.9%, with hemoglobin A1c now 5.5% and liver tests normal",
              "plan": [
                "Continue tirzepatide 5 mg weekly; increase to 7.5 mg in four weeks if tolerated"
              ]
            },
            {
              "problem_id": "PRB-007",
              "display": "Obstructive sleep apnea on CPAP",
              "assessment": "Good adherence and normal sleepiness score; weight loss may lower the pressure needed",
              "plan": [
                "Continue CPAP; repeat sleep testing if weight loss reaches 10%"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "medication_safety",
              "measure": "Buprenorphine dose, withdrawal symptoms, cravings and other opioid use",
              "cadence": "Every four weeks once stable",
              "status": "completed_today",
              "detail": "16 mg daily; no other opioid; rare cravings",
              "guideline_ids": [
                "GL-ASAM-OUD-2020"
              ]
            },
            {
              "domain": "survey",
              "measure": "Weekly video visits while away",
              "cadence": "Weekly during engagements and tours",
              "status": "completed_today",
              "detail": "All three weekly visits on tour kept at the fixed time",
              "guideline_ids": [
                "GL-ASAM-OUD-2020"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Prescription drug monitoring program check",
              "cadence": "Before every controlled-substance prescription",
              "status": "completed_today",
              "detail": "Only this clinic's prescriptions",
              "guideline_ids": [
                "GL-CDC-PDMP",
                "GL-CDC-OPIOID-2022"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Urine drug test, including buprenorphine metabolite and fentanyl",
              "cadence": "At the start of treatment, then about monthly while doses are changing",
              "status": "completed_today",
              "detail": "Buprenorphine, norbuprenorphine and benzodiazepines present; no other opioid; fentanyl absent (narrative)",
              "guideline_ids": [
                "GL-ASAM-OUD-2020",
                "GL-CDC-OPIOID-2022"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Naloxone on hand and people taught to use it",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "On hand at home and in the tour bag",
              "guideline_ids": [
                "GL-CDC-OPIOID-2022"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Diazepam dose, withdrawal symptoms (anxiety, insomnia, tremor, sweats) and taper pace",
              "cadence": "Every two to four weeks during the taper",
              "status": "completed_today",
              "detail": "32 to 30 mg a day (6%) after five weeks at 32 mg; no withdrawal symptoms",
              "guideline_ids": [
                "GL-BZD-TAPER-2025"
              ]
            },
            {
              "domain": "survey",
              "measure": "Suicide-risk review, safety plan, means safety (locked medicines and firearms) and the 988 Suicide & Crisis Lifeline",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "No thoughts of suicide or self-harm; firearms and medicines locked",
              "guideline_ids": [
                "GL-SUICIDE-2024"
              ]
            },
            {
              "domain": "survey",
              "measure": "Mood (PHQ-9) and anxiety (GAD-7)",
              "cadence": "At each review",
              "status": "completed_today",
              "detail": "PHQ-9 4 (item 9 scored 0); GAD-7 5",
              "observation_ids": [
                "OBS-PHQ9-V5",
                "OBS-GAD7-V5"
              ],
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-USPSTF-DEP-2023"
              ]
            },
            {
              "domain": "examination",
              "measure": "Office and home blood pressure (target below 130/80)",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Office 122/78; home average 122/78",
              "guideline_ids": [
                "GL-AHA-HTN-2025",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Potassium and creatinine after starting an angiotensin receptor blocker",
              "cadence": "Two to four weeks after starting, then every six months",
              "status": "completed_today",
              "detail": "Potassium 4.3, creatinine 1.02",
              "observation_ids": [
                "OBS-K-V5",
                "OBS-CR-V5",
                "OBS-EGFR-V5"
              ],
              "guideline_ids": [
                "GL-AHA-HTN-2025",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Hemoglobin A1c in prediabetes",
              "cadence": "Every three to six months during treatment",
              "status": "completed_today",
              "detail": "5.5%, from 5.8%",
              "observation_ids": [
                "OBS-A1C-V5"
              ],
              "guideline_ids": [
                "GL-AGA-OBESITY-2022",
                "GL-SURMOUNT-OSA-2024"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Liver tests (ALT, AST, GGT)",
              "cadence": "Three to six months after an abnormal result",
              "status": "completed_today",
              "detail": "ALT 44, AST 33, GGT 55 U/L, all normal, from 72, 52 and 78",
              "observation_ids": [
                "OBS-ALT-V5",
                "OBS-AST-V5",
                "OBS-GGT-V5"
              ],
              "guideline_ids": [
                "GL-AGA-OBESITY-2022",
                "GL-SURMOUNT-OSA-2024"
              ]
            },
            {
              "domain": "examination",
              "measure": "Weight and BMI",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "102.6 kg, BMI 30.6; down 6.4 kg",
              "guideline_ids": [
                "GL-AGA-OBESITY-2022",
                "GL-SURMOUNT-OSA-2024"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Tirzepatide tolerance: nausea, vomiting, constipation, abdominal pain",
              "cadence": "At each dose step",
              "status": "completed_today",
              "detail": "5 mg for five weeks: nausea once; no vomiting or constipation",
              "guideline_ids": [
                "GL-AGA-OBESITY-2022",
                "GL-SURMOUNT-OSA-2024"
              ]
            },
            {
              "domain": "survey",
              "measure": "CPAP adherence (device data) and sleepiness (Epworth, recorded as narrative)",
              "cadence": "Within the first 30 to 90 days, then at each review",
              "status": "completed_today",
              "detail": "88% of nights; Epworth 6",
              "guideline_ids": [
                "GL-AASM-PAP-2019",
                "GL-AASM-DX-2017"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Bowel frequency, straining and alarm features",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Daily or every other day",
              "guideline_ids": [
                "GL-AGA-OIC-2019",
                "GL-AGA-ACG-CIC-2023"
              ]
            },
            {
              "domain": "examination",
              "measure": "Glaucoma: drop adherence, eye symptoms, medicines that raise eye pressure or close the angle, and ophthalmology follow-up",
              "cadence": "Every visit; ophthalmology every three to six months while recently controlled",
              "status": "completed_today",
              "detail": "No eye symptoms; drops nightly; next ophthalmology visit in three to six months",
              "guideline_ids": [
                "GL-AAO-POAG-2020",
                "GL-CMID-2026"
              ]
            }
          ],
          "follow_up": "Second hepatitis B vaccine dose given today. Review in four weeks with the next taper step; influenza vaccine then",
          "guideline_ids": [
            "GL-ASAM-OUD-2020",
            "GL-CDC-OPIOID-2022",
            "GL-BZD-TAPER-2025",
            "GL-AHA-HTN-2025",
            "GL-AGA-OBESITY-2022",
            "GL-SURMOUNT-OSA-2024",
            "GL-AASM-PAP-2019",
            "GL-CMID-2026"
          ]
        }
      },
      {
        "id": "ENC-006",
        "display": "Periodic adult preventive visit",
        "status": "finished",
        "date": "2026-08-14",
        "visit_type": "preventive_adult",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "86013001",
          "display": "Periodic reevaluation and management of healthy individual",
          "validation_status": "validated",
          "validated_on": "2026-11-05"
        },
        "documentation": {
          "chief_complaint": "Periodic adult preventive visit",
          "billing_note": "CPT 99395 (periodic preventive medicine, established patient, age 18 to 39) with CPT 99497 (advance care planning), both on the same day",
          "health_risk_assessment_method": "Completed by the patient on a tablet in the waiting room and reviewed with him by Dr. Ashby-Nakagawa",
          "hpi": {
            "narrative": "Mr. Presley is a 39-year-old singer with opioid use disorder on buprenorphine, a benzodiazepine use disorder on a slow diazepam taper, stage 2 hypertension, obesity with prediabetes, obstructive sleep apnea on CPAP, opioid-induced constipation and glaucoma, who comes for his yearly preventive visit one week after his three-week review and five days before a Las Vegas engagement. He has taken buprenorphine 16 mg every morning without withdrawal and with few cravings. He took the first diazepam step, to 36 mg a day, a week ago and noticed only slightly worse sleep for two nights. He took his first tirzepatide dose a week ago and had mild nausea for a day. He uses CPAP most nights and feels more awake in the afternoon. His bowels open every one to two days. He has not had a tetanus booster in more than ten years and has never been tested for HIV or hepatitis.",
            "elements": [
              {
                "label": "Visit",
                "value": "Periodic adult preventive visit, age 39"
              },
              {
                "label": "Buprenorphine",
                "value": "16 mg daily for four weeks; few cravings"
              },
              {
                "label": "Diazepam",
                "value": "36 mg a day since one week ago"
              },
              {
                "label": "Tirzepatide",
                "value": "First 2.5 mg dose a week ago; mild nausea for a day"
              },
              {
                "label": "Mood",
                "value": "PHQ-9 5; item 9 scored 0"
              },
              {
                "label": "Medicines",
                "value": "Buprenorphine with naloxone 16 mg daily; diazepam 36 mg a day; amlodipine with valsartan; tirzepatide 2.5 mg weekly; polyethylene glycol; latanoprost; naloxone spray on hand"
              }
            ]
          },
          "health_risk_assessment": [
            {
              "domain": "Self-rated health",
              "finding": "Fair, and better than a month ago"
            },
            {
              "domain": "Psychosocial",
              "finding": "Busy professional life; close friends who work with him; worried about how the engagement will go during treatment"
            },
            {
              "domain": "Alcohol",
              "finding": "None; AUDIT-C 0"
            },
            {
              "domain": "Tobacco",
              "finding": "Never"
            },
            {
              "domain": "Other substances",
              "finding": "Only the medicines prescribed by this clinic since intake; DAST-10 7 at intake, now in treatment"
            },
            {
              "domain": "Physical activity",
              "finding": "Karate practice twice a week and walks on the grounds most days"
            },
            {
              "domain": "Nutrition",
              "finding": "Moving the main meal earlier; fewer late-night meals"
            },
            {
              "domain": "Sleep",
              "finding": "Seven to eight hours with CPAP; less afternoon sleepiness"
            },
            {
              "domain": "Safety at home",
              "finding": "Feels safe; firearms now locked and unloaded with ammunition separate"
            },
            {
              "domain": "Road safety",
              "finding": "Wears a seat belt; not driving himself until the sleepiness has resolved"
            },
            {
              "domain": "Activities of daily living",
              "finding": "Independent"
            },
            {
              "domain": "Hearing and vision",
              "finding": "Wears tinted glasses for light sensitivity; ophthalmology follow-up planned next month"
            },
            {
              "domain": "Oral health",
              "finding": "Dental visit in the past year"
            }
          ],
          "ros": [
            {
              "system": "Constitutional",
              "status": "negative",
              "finding": "Energy improving; weight down 1.4 kg since intake"
            },
            {
              "system": "Eyes",
              "status": "negative",
              "finding": "No eye pain, halos or change in vision"
            },
            {
              "system": "Ears, nose, mouth, and throat",
              "status": "negative",
              "finding": "No dry mouth from CPAP"
            },
            {
              "system": "Cardiovascular",
              "status": "negative",
              "finding": "No chest pain, palpitations or ankle swelling"
            },
            {
              "system": "Respiratory",
              "status": "negative",
              "finding": "No cough or breathlessness; snoring stopped on CPAP"
            },
            {
              "system": "Gastrointestinal",
              "status": "positive",
              "finding": "Mild nausea for a day after the first tirzepatide dose; bowels every one to two days"
            },
            {
              "system": "Genitourinary",
              "status": "negative",
              "finding": "No urinary symptoms"
            },
            {
              "system": "Musculoskeletal",
              "status": "positive",
              "finding": "Occasional neck and back stiffness after practice"
            },
            {
              "system": "Integumentary",
              "status": "negative",
              "finding": "No rash or injection-site reaction"
            },
            {
              "system": "Neurological",
              "status": "negative",
              "finding": "No tremor, headaches or numbness"
            },
            {
              "system": "Psychiatric",
              "status": "negative",
              "finding": "PHQ-9 5; no thoughts of suicide or self-harm; cravings low"
            }
          ],
          "exam": [
            {
              "system": "Constitutional",
              "finding": "Well; weight 107.6 kg, BMI 32.1; blood pressure 126/80; pulse 74"
            },
            {
              "system": "Eyes",
              "finding": "Pupils equal and reactive; no redness"
            },
            {
              "system": "Neck",
              "finding": "Circumference 44 cm; no thyroid enlargement"
            },
            {
              "system": "Cardiovascular",
              "finding": "Regular rhythm; no murmur; no edema"
            },
            {
              "system": "Respiratory",
              "finding": "Clear"
            },
            {
              "system": "Abdomen",
              "finding": "Soft, non-tender; liver edge not palpable; no distension"
            },
            {
              "system": "Skin",
              "finding": "Injection site clean; no track marks"
            },
            {
              "system": "Neurological",
              "finding": "Normal; no tremor"
            }
          ],
          "assessment_plan": [
            {
              "display": "Periodic adult preventive visit completed",
              "assessment": "Health risk assessment reviewed and the prevention plan updated. Lipids: total cholesterol 214, HDL 38, LDL 140 and triglycerides 180 mg/dL, a pattern that fits obesity and prediabetes. At 39 the pooled cohort equations do not apply; his 10-year risk by the AHA PREVENT equations is low, so a statin is not indicated now, and weight loss, activity and blood pressure control are the main steps",
              "plan": [
                "Repeat lipids after six months of weight treatment",
                "HIV, hepatitis C and hepatitis B tests drawn today",
                "Next preventive visit in one year"
              ]
            },
            {
              "problem_id": "PRB-004",
              "display": "Opioid use disorder on buprenorphine",
              "assessment": "Stable on 16 mg with few cravings. Safety reviewed: no thoughts of suicide or self-harm; naloxone in the house and the tour bag; firearms locked",
              "plan": [
                "Prescriptions for the engagement sent to one named pharmacy in Las Vegas",
                "Weekly video visits while he is away"
              ]
            },
            {
              "problem_id": "PRB-002",
              "display": "Obesity, class 1, with prediabetes",
              "assessment": "Weight down 1.4 kg since intake; tolerating the first tirzepatide dose",
              "plan": [
                "Continue tirzepatide 2.5 mg weekly",
                "Intensive behavioral counseling with a dietitian, by video during the engagement"
              ]
            }
          ],
          "prevention_plan": [
            {
              "service": "Blood pressure screening",
              "status": "completed_today",
              "detail": "126/80 mmHg on treatment; home average 128/82",
              "guideline_ids": [
                "GL-USPSTF-AB",
                "GL-AHA-HTN-2025"
              ]
            },
            {
              "service": "Lipid screening and cardiovascular risk",
              "status": "completed_today",
              "detail": "Total cholesterol 214, HDL 38, LDL 140, triglycerides 180 mg/dL; low 10-year risk; statin not indicated at 39",
              "guideline_ids": [
                "GL-USPSTF-STATIN-2022"
              ]
            },
            {
              "service": "Diabetes screening",
              "status": "up_to_date",
              "detail": "Hemoglobin A1c 5.8% at intake, prediabetes; treated with weight loss",
              "guideline_ids": [
                "GL-USPSTF-DM-2021"
              ]
            },
            {
              "service": "Obesity behavioral counseling",
              "status": "completed_today",
              "detail": "BMI 32.1; intensive counseling with a dietitian arranged",
              "guideline_ids": [
                "GL-USPSTF-OBESITY-2018",
                "GL-AGA-OBESITY-2022"
              ]
            },
            {
              "service": "Unhealthy drug use screening",
              "status": "up_to_date",
              "detail": "DAST-10 7 at intake; in treatment",
              "guideline_ids": [
                "GL-USPSTF-DRUG-2020"
              ]
            },
            {
              "service": "Unhealthy alcohol use",
              "status": "up_to_date",
              "detail": "AUDIT-C 0 at intake",
              "guideline_ids": [
                "GL-USPSTF-ALC-2018"
              ]
            },
            {
              "service": "Tobacco use",
              "status": "not_indicated",
              "detail": "Never used tobacco",
              "guideline_ids": [
                "GL-USPSTF-AB"
              ]
            },
            {
              "service": "Depression screening",
              "status": "completed_today",
              "detail": "PHQ-9 5, item 9 scored 0",
              "guideline_ids": [
                "GL-USPSTF-DEP-2023",
                "GL-CMID-2026"
              ]
            },
            {
              "service": "HIV screening",
              "status": "ordered",
              "detail": "Once for all adults; drawn today with his agreement",
              "guideline_ids": [
                "GL-USPSTF-HIV-2019"
              ]
            },
            {
              "service": "Hepatitis C screening",
              "status": "ordered",
              "detail": "Once for all adults; drawn today",
              "guideline_ids": [
                "GL-USPSTF-HCV-2020"
              ]
            },
            {
              "service": "Hepatitis B screening",
              "status": "ordered",
              "detail": "Triple panel once for all adults; drawn today",
              "guideline_ids": [
                "GL-CDC-HBV-2023"
              ]
            },
            {
              "service": "Colorectal cancer screening",
              "status": "not_indicated",
              "detail": "Begins at 45",
              "guideline_ids": [
                "GL-USPSTF-CRC-2021"
              ]
            },
            {
              "service": "Tetanus, diphtheria, and pertussis",
              "status": "completed_today",
              "detail": "Tdap given today; last booster more than ten years ago",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "Hepatitis B vaccine",
              "status": "due",
              "detail": "Recommended for adults 19 to 59; to start once today's serology shows he is not immune",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "Influenza vaccine",
              "status": "due",
              "detail": "When the autumn vaccine is available",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "COVID-19 vaccine",
              "status": "due",
              "detail": "Discussed under shared clinical decision-making; to decide in the autumn",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "Eye examination",
              "status": "up_to_date",
              "detail": "Under his ophthalmologist's care for glaucoma; next visit next month",
              "guideline_ids": [
                "GL-AAO-POAG-2020",
                "GL-CMID-2026"
              ]
            }
          ],
          "advance_care_planning": "Voluntary advance care planning discussion of about 20 minutes, with his consent. He named a health care agent, a long-time friend who works with him, and a health care proxy form was completed; the agent is recorded in the chart and is not named here. He said that what matters most to him is being able to sing and to be there for the people who depend on him, and that he would want full treatment, including resuscitation and breathing support, after an overdose or other sudden illness. The plan will be revisited yearly or after any serious illness.",
          "follow_up": "Las Vegas engagement with weekly video visits; ten-week review after he returns. HIV, hepatitis C and hepatitis B results by phone. Next preventive visit in one year",
          "guideline_ids": [
            "GL-PREV-2026",
            "GL-USPSTF-AB",
            "GL-USPSTF-STATIN-2022",
            "GL-USPSTF-OBESITY-2018",
            "GL-USPSTF-DRUG-2020",
            "GL-CDC-IMZ-2026"
          ]
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic periodic preventive visit.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "ENC-007",
        "display": "Same-day sick visit for low back pain",
        "status": "finished",
        "date": "2026-09-09",
        "visit_type": "sick",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "185345009",
          "display": "Encounter for symptom",
          "validation_status": "validated",
          "validated_on": "2026-11-05"
        },
        "documentation": {
          "chief_complaint": "Low back pain for two days after karate practice",
          "billing_note": "Problem-oriented office visit, established patient",
          "hpi": {
            "narrative": "Mr. Presley asked for a same-day visit. Two days ago, a week after returning from his Las Vegas engagement, he twisted while practicing karate and felt a sharp pain across the left lower back. The pain is worse when he bends, stands up from a chair or turns in bed, and eases lying on his side with heat. It does not go down his legs. He has no numbness, weakness, bladder or bowel change, numbness in the saddle area, fever or chills, and no history of cancer or injected drugs. He rates the pain 7 out of 10. He has taken his usual buprenorphine 16 mg each morning, no other opioid and no extra diazepam, and he is worried that the pain will make him want his old pills and that it will not settle before the tour in eighteen days. The prescription drug monitoring program shows only this clinic's prescriptions.",
            "elements": [
              {
                "label": "Onset",
                "value": "Two days ago, twisting during karate practice"
              },
              {
                "label": "Location",
                "value": "Left lower back, without radiation"
              },
              {
                "label": "Duration",
                "value": "Two days"
              },
              {
                "label": "Character",
                "value": "Sharp, with spasm"
              },
              {
                "label": "Severity",
                "value": "7 of 10"
              },
              {
                "label": "Timing",
                "value": "Worse with bending, rising and turning"
              },
              {
                "label": "Context",
                "value": "Buprenorphine 16 mg daily; tour in eighteen days"
              },
              {
                "label": "Modifying factors",
                "value": "Better lying on his side with heat"
              },
              {
                "label": "Associated signs and symptoms",
                "value": "No leg pain, numbness, weakness, bladder or bowel change, or fever"
              }
            ]
          },
          "ros": [
            {
              "system": "Musculoskeletal",
              "status": "positive",
              "finding": "Left lower back pain and spasm"
            },
            {
              "system": "Neurological",
              "status": "negative",
              "finding": "No leg weakness, numbness or saddle anesthesia"
            },
            {
              "system": "Genitourinary",
              "status": "negative",
              "finding": "No retention or incontinence"
            },
            {
              "system": "Constitutional",
              "status": "negative",
              "finding": "No fever, chills or unintended weight loss"
            },
            {
              "system": "Psychiatric",
              "status": "negative",
              "finding": "Worried about cravings; no thoughts of suicide or self-harm"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Uncomfortable when moving; blood pressure 134/84, pulse 84, temperature 36.7 °C"
            },
            {
              "system": "Back",
              "finding": "Tender spasm of the left lumbar paraspinal muscles; no midline tenderness; flexion limited by pain"
            },
            {
              "system": "Neurological",
              "finding": "Straight-leg raise negative both sides; strength, reflexes and sensation normal in the legs; normal gait"
            },
            {
              "system": "Abdomen",
              "finding": "Soft, non-tender"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-009",
              "display": "Acute low back strain",
              "assessment": "A muscular strain without radiculopathy or red flags; imaging would not help. Buprenorphine itself gives pain relief that lasts six to eight hours, so splitting the same daily dose is the first step; a full-agonist opioid is not added because he is in early recovery and it would compete with buprenorphine. A muscle relaxant is avoided because it would add sedation to diazepam and his sleep apnea",
              "plan": [
                "Take buprenorphine as one 8 mg film twice daily instead of 16 mg once, the same total",
                "Naproxen 500 mg twice daily with food for five days; check home blood pressure",
                "Heat, gentle walking and staying active; no bed rest",
                "No imaging; physical therapy if not much better in two weeks",
                "Return at once for leg weakness, numbness, bladder or bowel change, or fever"
              ]
            },
            {
              "problem_id": "PRB-004",
              "display": "Opioid use disorder on buprenorphine",
              "assessment": "Pain is a known trigger for cravings; he raised it himself, which is a strength. Safety reviewed: no thoughts of suicide or self-harm; naloxone on hand",
              "plan": [
                "A phone check in three days",
                "Counseling session this week moved earlier"
              ]
            },
            {
              "problem_id": "PRB-005",
              "display": "Benzodiazepine use disorder on a diazepam taper",
              "assessment": "No extra diazepam taken; no taper step during an acute illness",
              "plan": [
                "The next step will be decided at the ten-week review"
              ]
            }
          ],
          "follow_up": "Phone check in three days. Ten-week review in two weeks, before the tour. Return sooner as above",
          "guideline_ids": [
            "GL-ACP-LBP-2017",
            "GL-CDC-OPIOID-2022",
            "GL-ASAM-OUD-2020"
          ]
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic unscheduled sick visit; the injury is not a historical claim.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      }
    ],
    "vital_sign_sets": [
      {
        "id": "VSET-001",
        "date": "2026-07-10",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 183,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 109.0,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 32.5,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 154,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 98,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 94,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.8,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 96,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs; no measurement from his lifetime is used.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "VSET-002",
        "date": "2026-07-17",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 183,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 108.6,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 32.4,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 146,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 94,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 102,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 18,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 37.0,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 96,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs; no measurement from his lifetime is used.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "VSET-003",
        "date": "2026-08-07",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 183,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 108.2,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 32.3,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 128,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 82,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 76,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 14,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.7,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 97,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs; no measurement from his lifetime is used.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "VSET-004",
        "date": "2026-09-23",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 183,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 105.1,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 31.4,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 126,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 80,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 74,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 14,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.6,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 97,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs; no measurement from his lifetime is used.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "VSET-005",
        "date": "2026-10-28",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 183,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 102.6,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 30.6,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 122,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 78,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 70,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 14,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.6,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 98,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs; no measurement from his lifetime is used.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "VSET-006",
        "date": "2026-08-14",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 183,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 107.6,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 32.1,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 126,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 80,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 74,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 14,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.6,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 97,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs at the preventive visit.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "VSET-007",
        "date": "2026-09-09",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 183,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 106.0,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 31.7,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 134,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 84,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 84,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.7,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 97,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic vital signs at the sick visit, in pain.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      }
    ],
    "social_history": [
      {
        "id": "SOC-001",
        "display": "Singer and performer since his teens; long engagements in Las Vegas and multi-week concert tours with two shows on some nights; between tours he is at his home in Memphis. A three-week Las Vegas engagement begins in about six weeks and a tour after that",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0002",
            "CLM-0015"
          ],
          "synthetic_reason": "Synthetic modern work history anchored to his documented career and 1974 schedule.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "SOC-002",
        "display": "Lives at his home in Memphis with household staff and friends who work for him and travel with him on tour",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic household history; no family member is named or given a role.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "SOC-003",
        "display": "Prescriptions from five prescribers filled at three pharmacies over the past year, by the prescription drug monitoring program; says he started opioids for back and neck pain from performing, and sedatives for sleep after shows; also a nonprescription diphenhydramine sleep aid most nights, stopped today because of his glaucoma and the sedatives; no pills from any source other than a prescription or a pharmacy shelf; never injected",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0009",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic modern medication history anchored to the documented drugs from several prescribers; written without judgment.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "SOC-004",
        "display": "Alcohol: none (AUDIT-C 0). Tobacco: never",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0011"
          ],
          "synthetic_reason": "Synthetic history anchored to the documented report that he neither smoked nor drank.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "SOC-005",
        "display": "Eats one large meal after shows late at night; snacks on the tour bus; little activity between tours apart from karate practice",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic nutrition and activity history, recorded without stigma.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "SOC-006",
        "display": "Keeps several firearms at home; agreed today to store them locked and unloaded, with ammunition separate, while the medicines are being changed",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic firearm-access history for the safety assessment.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "SOC-007",
        "display": "Strengths: devotion to his audience and his music, his faith and gospel singing, loyalty to the people around him, and his own decision to change how he takes his medicines",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic strengths.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      }
    ],
    "functional_status": [
      {
        "id": "FUNC-001",
        "display": "Independent in all activities; sleeps late after shows and is drowsy through the afternoon; has fallen asleep in the car as a passenger; does not drive himself at present. Epworth Sleepiness Scale 14 (excessive daytime sleepiness); STOP-Bang 6 of 8 (snoring, tiredness, observed pauses, high blood pressure, BMI above 35 not met, neck 44 cm, male); neck circumference 44 cm",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic functional status and sleep screening at intake.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      }
    ],
    "mental_status": [
      {
        "id": "MSE-001",
        "display": "Polite, warm and soft-spoken; a little slowed with small pupils, without slurred speech; no signs of withdrawal; candid once reassured that the visit is not about blame",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic mental-status finding.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "MSE-002",
        "display": "Mood tired and worried; PHQ-9 8 with item 9 scored 0, GAD-7 9; no thoughts of suicide or self-harm now or in the past",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic mental-status finding; not a claim about his real mood.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      }
    ],
    "safety_assessment": {
      "id": "SAFE-001",
      "date": "2026-07-10",
      "current_ideation": "absent",
      "intent": "absent",
      "plan": "absent",
      "access_reviewed": true,
      "protective_factors": [
        "His music and his audience",
        "His faith",
        "The people close to him who travel with him",
        "His own decision to seek help now",
        "Engagement in primary care and the addiction medicine plan"
      ],
      "disposition": "Outpatient care with close follow-up. No current or past suicidal ideation. Risk factors reviewed: opioid and sedative use disorders under assessment, taking opioids with benzodiazepines, sleep apnea symptoms, firearms at home, and the stress of touring. Means safety: firearms to be stored locked and unloaded with ammunition separate; all controlled medicines in a locked box, with unused tablets from earlier prescriptions taken back to a pharmacy; seven-day supplies; naloxone at home and in the tour bag, with two people around him taught to use it. A written safety plan was made with him, and the 988 Suicide & Crisis Lifeline (call or text 988) was saved in his phone. Safety is reviewed at every visit",
      "provenance": {
        "evidence_grade": "S",
        "claim_ids": [
          "CLM-0003",
          "CLM-0009",
          "CLM-0010"
        ],
        "synthetic_reason": "Synthetic present-day structured safety assessment required by the substance use codes; it records no suicidal ideation and makes no claim about his real mental health.",
        "author": "The Human Record generator",
        "created": "2026-11-05T20:00:00-05:00"
      }
    },
    "consultation": {
      "referral": {
        "question": "Long-term prescription opioids and benzodiazepines from five prescribers, with fatigue, weight gain, constipation, daytime sleepiness and high blood pressure, in a 39-year-old touring singer who wants to change how he takes his medicines. Please assess for substance use disorders and advise on medication for opioid use disorder and a safe benzodiazepine plan",
        "urgency": "Within one week, on the day of his one-week primary care review, at his request before a Las Vegas engagement in five weeks",
        "pertinent_history": "Opioids for about five years for back and neck pain from performing, and sedatives for sleep after shows. A hospital stay some years ago in which he was withdrawn from opioids. The monitoring program shows five prescribers and three pharmacies in the past year: hydromorphone 4 mg about five a day and oxycodone 10 mg with acetaminophen about three a day (about 145 MME), diazepam 10 mg three times daily, alprazolam 1 mg up to three a day, and phentermine 37.5 mg each morning (stopped today because of hypertension and glaucoma), with a nonprescription diphenhydramine sleep aid (also stopped). He takes more than prescribed, has tried to cut down, and has cravings; he has never injected and uses no illicit drugs or alcohol (AUDIT-C 0; DAST-10 7). PHQ-9 8 and GAD-7 9, item 9 scored 0; no suicidal thoughts; structured safety assessment done, firearms to be locked. Blood pressure 154/98, pulse 94; BMI 32.5; ALT 72, AST 52, GGT 78; hemoglobin A1c 5.8%; ECG normal, QTc 436 ms. STOP-Bang 6, Epworth 14; in-laboratory polysomnography booked. Glaucoma on latanoprost. Today: naloxone, a single-prescriber agreement, seven-day supplies of his current opioids and benzodiazepines at the verified doses, a locked box and take-back; he preferred to discuss buprenorphine with the specialist before starting",
        "questions": [
          "Does he meet DSM-5-TR criteria for opioid and sedative use disorders, and how severe?",
          "Should he start buprenorphine, and how: in the office or at home, standard or low-dose start?",
          "How should the two benzodiazepines be managed alongside buprenorphine, and at what taper pace?",
          "What monitoring do you advise (urine testing, monitoring program, visit frequency, naloxone)?",
          "How should care be planned around a Las Vegas engagement and a tour this autumn?"
        ]
      },
      "consultant_note": {
        "history": "Mr. Presley, a 39-year-old singer, is seen at the request of Dr. Ashby-Nakagawa. He began opioids about five years ago for back and neck pain from performing, and benzodiazepines for sleep after late shows. Over time he took more than prescribed, found more than one prescriber, and felt sick and craved them when he ran short; a hospital stay some years ago withdrew him from opioids, and he restarted within months. He has never injected or used illicit drugs and does not drink. For the past week he has taken only this clinic's prescriptions. He last took hydromorphone about 18 hours ago and oxycodone about 20 hours ago, as planned, and is in mild to moderate withdrawal. He took diazepam and alprazolam last night. He has a Las Vegas engagement in five weeks and a tour after it and wants to start treatment now",
        "data_reviewed": "Dr. Ashby-Nakagawa's intake note and the prescription drug monitoring program report (five prescribers, three pharmacies, about 145 MME a day with two benzodiazepines). DAST-10 7, AUDIT-C 0, PHQ-9 8, GAD-7 9. The structured safety assessment. Liver tests mildly raised; ECG normal with a QTc of 436 ms. In-laboratory polysomnography three days ago: apnea-hypopnea index 26 an hour, central apnea index 4. Point-of-care urine test today: hydromorphone, oxycodone and benzodiazepines; no fentanyl. COWS 12",
        "exam": [
          {
            "system": "General",
            "finding": "Restless, yawning; blood pressure 146/94, pulse 102, temperature 37.0 °C"
          },
          {
            "system": "Eyes",
            "finding": "Pupils 5 mm and reactive; lacrimation"
          },
          {
            "system": "Skin",
            "finding": "Piloerection; sweating; no injection marks"
          },
          {
            "system": "Neurological",
            "finding": "Mild tremor of the outstretched hands; alert and oriented"
          }
        ],
        "assessment": [
          {
            "problem_id": "PRB-004",
            "display": "Opioid use disorder, severe",
            "assessment": "Seven DSM-5-TR criteria: larger amounts than intended, unsuccessful efforts to cut down, much time spent obtaining prescriptions, craving, continued use despite physical problems, tolerance and withdrawal, which count here because the opioids were not taken as prescribed. Buprenorphine lowers the risk of overdose and death and fits a touring life better than methadone, which needs daily clinic dosing. A standard start is suitable because his opioids are short-acting and he is already in moderate withdrawal; a low-dose start would be chosen for someone who cannot tolerate withdrawal or is on methadone"
          },
          {
            "problem_id": "PRB-005",
            "display": "Sedative, hypnotic, or anxiolytic use disorder (benzodiazepines), moderate",
            "assessment": "Five criteria, including withdrawal. Abrupt stopping risks seizures. The 2025 joint guideline allows a switch to a single longer-acting benzodiazepine, advises against tapering during other major changes, and suggests reductions of about 5 to 10% every two to four weeks, adjusted to symptoms. Taking a benzodiazepine is not a reason to withhold buprenorphine, but the combination raises the risk of sedation and slowed breathing, especially with sleep apnea"
          },
          {
            "problem_id": "PRB-007",
            "display": "Obstructive sleep apnea",
            "assessment": "Moderate obstructive sleep apnea with a small central component; CPAP is important while he takes buprenorphine and diazepam, and no additional night sedative should be used"
          }
        ],
        "recommendations": [
          "Start buprenorphine with naloxone in the office today at COWS 12: 4 mg, then 4 mg after an hour if withdrawal persists; 16 mg daily from tomorrow, adjusted up to 24 mg for cravings or withdrawal",
          "Stop hydromorphone and oxycodone today and take back the remaining tablets; no full-agonist opioid from any prescriber",
          "Combine diazepam and alprazolam into diazepam 10 mg four times daily (40 mg a day); no taper step until buprenorphine has been stable for two to three weeks, then reduce by about 10% every four weeks or so, pausing for engagements, illness or withdrawal symptoms; CBT for anxiety and insomnia",
          "Naloxone at home and in the tour bag, with people around him trained; no alcohol, no other sedatives, and CPAP every night",
          "A single prescriber and one named pharmacy, a monitoring program check before each prescription, seven-day supplies for the first month then two weeks, and a urine drug test at the start, about a month later and when doses change",
          "Weekly contact for the first month, counseling, and safety review at every visit",
          "For engagements and tours: no medication change in the week before, prescriptions sent to one named pharmacy where he will be, weekly video visits, and a written plan for missed doses",
          "For acute pain: continue buprenorphine and split the dose, add an NSAID or other non-opioid treatment, and call this clinic before any other prescriber gives an opioid"
        ],
        "communication": "Discussed with Dr. Ashby-Nakagawa, who saw him the same day. The diagnoses and the plan were explained to Mr. Presley without blame; he asked whether buprenorphine would affect his voice or his energy on stage, was told that it should not once the dose is steady, and chose to start today",
        "follow_up": "Addiction medicine will see him again in three months or sooner if cravings return or the taper stalls; Dr. Ashby-Nakagawa prescribes and follows him, with weekly contact in the first month"
      },
      "guideline_ids": [
        "GL-ASAM-OUD-2020",
        "GL-CDC-OPIOID-2022",
        "GL-BZD-TAPER-2025",
        "GL-CDC-PDMP",
        "GL-AASM-PAP-2019",
        "GL-SUICIDE-2024"
      ]
    }
  },
  "care_plan": {
    "health_concerns": [
      {
        "id": "HC-001",
        "display": "He is tired all the time, sleepy in the afternoon and cannot keep up the energy his shows need",
        "status": "active",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic patient-centered concern.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "HC-002",
        "display": "He has put on weight and feels bloated and constipated, and is self-conscious about it on stage",
        "status": "active",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic patient-centered concern anchored to his documented weight gain.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "HC-003",
        "display": "He wants to stop needing so many pills without going through withdrawal or missing a show",
        "status": "active",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0009",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic patient-centered concern anchored to the documented prescribed drugs.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      }
    ],
    "goals": [
      {
        "id": "GOAL-001",
        "display": "Stop full-agonist opioids and stabilize on buprenorphine without significant withdrawal",
        "status": "completed",
        "target_date": "2026-08-07",
        "outcome": "Buprenorphine 16 mg a day since the consultation; no withdrawal after the first day; cravings low",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic opioid use disorder goal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "GOAL-002",
        "display": "One prescriber and one pharmacy for all controlled medicines",
        "status": "completed",
        "target_date": "2026-09-23",
        "outcome": "Monitoring program shows only this clinic's prescriptions since intake",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic safe-prescribing goal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "GOAL-003",
        "display": "Lower the diazepam dose slowly, 5 to 10% every two to four weeks, toward stopping",
        "status": "active",
        "target_date": "2026-10-28",
        "outcome": "40 mg a day after the alprazolam was combined into it, to 30 mg at four months; no withdrawal symptoms; taper continuing",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic taper goal; the end of the taper falls after the episode.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "GOAL-004",
        "display": "Home blood pressure below 130/80",
        "status": "completed",
        "target_date": "2026-08-07",
        "outcome": "Home average 146/94 to 126/80 on amlodipine and valsartan",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood pressure goal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "GOAL-005",
        "display": "Lose 5% or more of body weight",
        "status": "completed",
        "target_date": "2026-10-28",
        "outcome": "109.0 to 102.6 kg (5.9%) on tirzepatide, with more activity and earlier meals",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic weight goal set with him, without stigma.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "GOAL-006",
        "display": "CPAP on at least 70% of nights for four hours or more, with less daytime sleepiness",
        "status": "completed",
        "target_date": "2026-10-28",
        "outcome": "CPAP on 88% of nights; Epworth 14 to 6",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic sleep goal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "GOAL-007",
        "display": "A bowel movement at least every two days without straining",
        "status": "completed",
        "target_date": "2026-08-07",
        "outcome": "Every one to two days on buprenorphine and polyethylene glycol",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic constipation goal.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      }
    ],
    "interventions": [
      {
        "id": "INT-001",
        "display": "Safe prescribing of controlled drugs: a brown-bag reconciliation of every medicine, a prescription drug monitoring program check before every controlled prescription, a written single-prescriber agreement with one pharmacy, urine drug testing explained as part of care, seven-day supplies at first, a locked box, and take-back of unused tablets; no controlled drug stopped abruptly",
        "status": "completed",
        "guideline_ids": [
          "GL-CDC-OPIOID-2022",
          "GL-CDC-PDMP",
          "GL-BZD-TAPER-2025"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0009",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic safe-prescribing plan, the teaching point of the case.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "INT-002",
        "display": "Addiction medicine consultation to make the substance use diagnoses, start medication for opioid use disorder, and plan the benzodiazepine change and taper",
        "status": "completed",
        "guideline_ids": [
          "GL-ASAM-OUD-2020",
          "GL-BZD-TAPER-2025"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0009",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic specialist consultation.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "INT-003",
        "display": "Overdose prevention: naloxone nasal spray at home and in the tour bag, two people around him taught to use it, no alcohol or other sedatives, and the danger of opioids with benzodiazepines and with the sleep apnea that is suspected explained",
        "status": "completed",
        "guideline_ids": [
          "GL-CDC-OPIOID-2022",
          "GL-ASAM-OUD-2020"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic naloxone plan.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "INT-004",
        "display": "Safety: a structured safety assessment, a written safety plan, firearms locked and unloaded with ammunition separate, the 988 Suicide & Crisis Lifeline, and safety review at every visit; PHQ-9 and GAD-7 at each review",
        "status": "completed",
        "guideline_ids": [
          "GL-SUICIDE-2024",
          "GL-USPSTF-DEP-2023",
          "GL-CMID-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic safety plan.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "INT-005",
        "display": "Buprenorphine for opioid use disorder: buprenorphine with naloxone started in the office at a COWS score above 8, 16 mg a day, weekly contact for the first month, prescriptions from this clinic only, counseling, and no tapering off while he is doing well; buprenorphine is not withheld because he takes a benzodiazepine",
        "status": "completed",
        "guideline_ids": [
          "GL-ASAM-OUD-2020",
          "GL-CDC-OPIOID-2022"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0009",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic opioid use disorder treatment decided at the consultation.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        },
        "recorded_date": "2026-07-17"
      },
      {
        "id": "INT-006",
        "display": "Benzodiazepine change and taper: alprazolam combined into diazepam (40 mg a day), held steady until buprenorphine is stable, then reduced by about 5 to 10% every two to four weeks, paused during engagements, illness or withdrawal symptoms, never stopped abruptly; CBT for anxiety and insomnia alongside; no Z-drug or other sedative in its place",
        "status": "completed",
        "guideline_ids": [
          "GL-BZD-TAPER-2025"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0009",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic taper plan decided at the consultation.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        },
        "recorded_date": "2026-07-17"
      },
      {
        "id": "INT-007",
        "display": "Hypertension: home readings confirmed stage 2 hypertension, so two first-line drugs were started in one pill (amlodipine with valsartan), with potassium and creatinine two to four weeks later, a target below 130/80, sodium reduction, activity and weight loss",
        "status": "completed",
        "guideline_ids": [
          "GL-AHA-HTN-2025",
          "GL-CMID-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0004"
          ],
          "synthetic_reason": "Synthetic hypertension plan decided at the consultation visit after home readings.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        },
        "recorded_date": "2026-07-17"
      },
      {
        "id": "INT-008",
        "display": "Obstructive sleep apnea: CPAP from the split-night titration, with adherence data reviewed at each visit and a travel machine for tours; no sedative added at night",
        "status": "completed",
        "guideline_ids": [
          "GL-AASM-PAP-2019",
          "GL-AASM-DX-2017"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic sleep plan decided after the polysomnogram.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        },
        "recorded_date": "2026-07-17"
      },
      {
        "id": "INT-009",
        "display": "Weight treated without stigma: earlier meals, protein and fiber, more walking and karate between tours, and tirzepatide once weekly, chosen because it also treats obstructive sleep apnea with obesity, raised slowly with a watch on nausea and constipation",
        "status": "completed",
        "guideline_ids": [
          "GL-AGA-OBESITY-2022",
          "GL-SURMOUNT-OSA-2024"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic weight plan decided once buprenorphine was stable.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        },
        "recorded_date": "2026-08-07"
      },
      {
        "id": "INT-010",
        "display": "Constipation on opioids: polyethylene glycol daily with senna as needed, fluids and fiber; a peripherally acting opioid antagonist only if these fail; an abdominal radiograph only for pain, distension or vomiting",
        "status": "completed",
        "guideline_ids": [
          "GL-AGA-OIC-2019",
          "GL-AGA-ACG-CIC-2023"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0004"
          ],
          "synthetic_reason": "Synthetic constipation plan.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "INT-011",
        "display": "Glaucoma: latanoprost continued, his ophthalmologist kept informed of every new medicine, no phentermine, decongestant or anticholinergic sleep aid, steroids only when essential and with his ophthalmologist's knowledge, and urgent care for eye pain with halos",
        "status": "completed",
        "guideline_ids": [
          "GL-AAO-POAG-2020",
          "GL-CMID-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0008"
          ],
          "synthetic_reason": "Synthetic glaucoma plan.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      },
      {
        "id": "INT-012",
        "display": "Performing and touring: no medication change in the week before an engagement, weekly video visits while away, controlled prescriptions sent only to one named pharmacy, a written plan for missed doses, naloxone and any prescribed devices in the tour bag, and a letter he controls for venues",
        "status": "completed",
        "guideline_ids": [
          "GL-ASAM-OUD-2020",
          "GL-BZD-TAPER-2025"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0002"
          ],
          "synthetic_reason": "Synthetic touring plan.",
          "author": "The Human Record generator",
          "created": "2026-11-05T20:00:00-05:00"
        }
      }
    ],
    "guidelines": [
      {
        "guideline_id": "GL-CDC-OPIOID-2022",
        "title": "CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022",
        "publisher": "Centers for Disease Control and Prevention (MMWR Recomm Rep 2022;71(3):1-95)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/36327391/",
        "version_or_year": "2022"
      },
      {
        "guideline_id": "GL-ASAM-OUD-2020",
        "title": "The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update",
        "publisher": "American Society of Addiction Medicine (J Addict Med 2020;14(2S Suppl 1):1-91)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/32511106/",
        "version_or_year": "2020"
      },
      {
        "guideline_id": "GL-BZD-TAPER-2025",
        "title": "Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits",
        "publisher": "American Society of Addiction Medicine and nine partner organizations (J Gen Intern Med 2025;40(12):2814-2859)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/40526204/",
        "version_or_year": "2025"
      },
      {
        "guideline_id": "GL-CDC-PDMP",
        "title": "Prescription Drug Monitoring Programs (PDMPs)",
        "publisher": "Centers for Disease Control and Prevention",
        "url": "https://www.cdc.gov/overdose-prevention/hcp/clinical-guidance/prescription-drug-monitoring-programs.html",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-AHA-HTN-2025",
        "title": "2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults",
        "publisher": "American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/40811497/",
        "version_or_year": "2025"
      },
      {
        "guideline_id": "GL-AGA-OBESITY-2022",
        "title": "AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity",
        "publisher": "American Gastroenterological Association (Gastroenterology 2022;163(5):1198-1225)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/36273831/",
        "version_or_year": "2022"
      },
      {
        "guideline_id": "GL-SURMOUNT-OSA-2024",
        "title": "Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity",
        "publisher": "N Engl J Med 2024;391(13):1193-1205",
        "url": "https://pubmed.ncbi.nlm.nih.gov/38912654/",
        "version_or_year": "2024"
      },
      {
        "guideline_id": "GL-AASM-DX-2017",
        "title": "Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline",
        "publisher": "American Academy of Sleep Medicine (J Clin Sleep Med 2017;13(3):479-504)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/28162150/",
        "version_or_year": "2017"
      },
      {
        "guideline_id": "GL-AASM-PAP-2019",
        "title": "Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline",
        "publisher": "American Academy of Sleep Medicine (J Clin Sleep Med 2019;15(2):335-343)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/30736887/",
        "version_or_year": "2019"
      },
      {
        "guideline_id": "GL-STOPBANG-2008",
        "title": "STOP questionnaire: a tool to screen patients for obstructive sleep apnea",
        "publisher": "Anesthesiology 2008;108(5):812-821",
        "url": "https://pubmed.ncbi.nlm.nih.gov/18431116/",
        "version_or_year": "2008"
      },
      {
        "guideline_id": "GL-AGA-OIC-2019",
        "title": "American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation",
        "publisher": "American Gastroenterological Association (Gastroenterology 2019;156(1):218-226)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/30340754/",
        "version_or_year": "2019"
      },
      {
        "guideline_id": "GL-AGA-ACG-CIC-2023",
        "title": "American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation",
        "publisher": "AGA and ACG (Gastroenterology 2023;164(7):1086-1106)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/37211380/",
        "version_or_year": "2023"
      },
      {
        "guideline_id": "GL-AAO-POAG-2020",
        "title": "Primary Open-Angle Glaucoma Preferred Practice Pattern",
        "publisher": "American Academy of Ophthalmology (Ophthalmology 2021;128(1):P71-P150)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/34933745/",
        "version_or_year": "2020"
      },
      {
        "guideline_id": "GL-SUICIDE-2024",
        "title": "VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide",
        "publisher": "United States Department of Veterans Affairs and Department of Defense",
        "url": "https://healthquality.va.gov/HEALTHQUALITY/guidelines/mh/srb/index.asp",
        "version_or_year": "2024"
      },
      {
        "guideline_id": "GL-USPSTF-DEP-2023",
        "title": "Depression and Suicide Risk in Adults: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-depression-suicide-risk-adults",
        "version_or_year": "2023"
      },
      {
        "guideline_id": "GL-CMID-2026",
        "title": "CMID: Clinical Monitoring Intelligence Database, hypertension, glaucoma, and depression, bipolar, and mood disorders monographs",
        "publisher": "Aether Forge",
        "url": "https://patrickrutledge.github.io/topthirty/",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-PREV-2026",
        "title": "Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements",
        "publisher": "Aether Forge",
        "url": "https://patrickrutledge.github.io/preventative_services/",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-USPSTF-AB",
        "title": "USPSTF A and B Recommendations",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-USPSTF-STATIN-2022",
        "title": "Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/statin-use-in-adults-preventive-medication",
        "version_or_year": "2022"
      },
      {
        "guideline_id": "GL-USPSTF-DM-2021",
        "title": "Prediabetes and Type 2 Diabetes: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-for-prediabetes-and-type-2-diabetes",
        "version_or_year": "2021"
      },
      {
        "guideline_id": "GL-USPSTF-OBESITY-2018",
        "title": "Weight Loss to Prevent Obesity-Related Morbidity and Mortality in Adults: Behavioral Interventions",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/obesity-in-adults-interventions",
        "version_or_year": "2018"
      },
      {
        "guideline_id": "GL-USPSTF-DRUG-2020",
        "title": "Unhealthy Drug Use: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/drug-use-illicit-screening",
        "version_or_year": "2020"
      },
      {
        "guideline_id": "GL-USPSTF-HIV-2019",
        "title": "Human Immunodeficiency Virus (HIV) Infection: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/human-immunodeficiency-virus-hiv-infection-screening",
        "version_or_year": "2019"
      },
      {
        "guideline_id": "GL-USPSTF-HCV-2020",
        "title": "Hepatitis C Virus Infection in Adolescents and Adults: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hepatitis-c-screening",
        "version_or_year": "2020"
      },
      {
        "guideline_id": "GL-CDC-HBV-2023",
        "title": "Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023",
        "publisher": "Centers for Disease Control and Prevention (MMWR Recommendations and Reports)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/36893044/",
        "version_or_year": "2023"
      },
      {
        "guideline_id": "GL-USPSTF-ALC-2018",
        "title": "Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/unhealthy-alcohol-use-in-adolescents-and-adults-screening-and-behavioral-counseling-interventions",
        "version_or_year": "2018"
      },
      {
        "guideline_id": "GL-USPSTF-CRC-2021",
        "title": "Colorectal Cancer: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
        "version_or_year": "2021"
      },
      {
        "guideline_id": "GL-CDC-IMZ-2026",
        "title": "Adult Immunization Schedule by Age",
        "publisher": "Centers for Disease Control and Prevention",
        "url": "https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-ACP-LBP-2017",
        "title": "Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians",
        "publisher": "American College of Physicians (Ann Intern Med 2017;166(7):514-530)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/28192789/",
        "version_or_year": "2017"
      }
    ]
  },
  "review": {
    "schema_validation": {
      "status": "not_started",
      "notes": "Run scripts/build.ps1 -Conformance."
    },
    "clinical_review": {
      "status": "not_started",
      "notes": "Awaiting clinician review; check the DSM-5-TR criteria counts (tolerance and withdrawal counted because use was not as prescribed), the MME totals, the one-week delay before buprenorphine at his choice with naloxone and seven-day supplies in between, the in-office induction, buprenorphine with a benzodiazepine, the alprazolam to diazepam conversion and the taper pace, amlodipine with valsartan as a single pill for stage 2 hypertension, tirzepatide for obesity with obstructive sleep apnea while on buprenorphine, in-laboratory polysomnography on opioids, stopping phentermine for glaucoma and blood pressure, and acute back pain treated by splitting the buprenorphine dose with naproxen."
    },
    "provenance_review": {
      "status": "not_started",
      "notes": "Sources: The New York Times obituary (1977), Graceland's official timeline, four UPI wire reports of the 1981 trial, the 1977 Rolling Stone report, a HISTORY article (2026), and the PubMed abstract of Zegers et al. (2025). The Commercial Appeal could not be reached and the biographies were not read. The cause of death is graded R and disputed; the steroid explanation of his glaucoma is R, probable; the megacolon account is R, possible."
    },
    "safe_messaging_review": {
      "status": "not_started",
      "notes": "Drug and mental-health claims are marked sensitive; the 1973 hospital stay and the trial testimony are recorded without detail beyond the reports; his death is recorded in one plain sentence and its disputed cause separately; person-first language; weight is described without stigma; the safety assessment gives the 988 Suicide & Crisis Lifeline and addresses means safety, including firearms. His physician appears only in documented history, with no modern decision or statement attributed to him; no living person is named, and nothing is attributed to his former wife or his daughter."
    }
  }
}
